



(51) International Patent Classification:

C12N 15/62 (2006.01) A61K 38/18 (2006.01)
C07K 14/495 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2016/024368

(22) International Filing Date:

25 March 2016 (25.03.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/138,886 26 March 2015 (26.03.2015) US

(71) Applicant: ACCELERON PHARMA INC. [US/US];
128 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: KUMAR, Ravindra; 421 Arlington Street, Acton, MA 01720 (US). GRINBERG, Asya; 37 Follen Road, Lexington, MA 02421 (US). SAKO, Dianne S.; 14 Mystic Street, Medford, MA 02155 (US).

(74) Agents: VARMA, Anita et al.; Ropes & Cray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: FOLLISTATIN-RELATED FUSION PROTEINS AND USES THEREOF




FIGURE 2

(57) Abstract: The present disclosure provides compositions and methods for inhibiting activity of TGFβ superfamily ligands, particularly ligands such as GDF8, GDF 11, activin A, activin B, activin C and activin E, in vertebrates, including rodents, primates, and particularly in humans. The compositions of the disclosure contain protein complex/fusion comprising a heteromeric Fc interaction pair to which a follistatin related polypeptide is covalently or non-covalently associated. The compositions maybe used to treat or prevent diseases or disorders that are associated with abnormal activity of a follistatin-related polypeptide and/or a follistatin ligand.

WO 2016/154601 A1

FOLLISTATIN-RELATED FUSION PROTEINS AND USES THEREOF

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/138,886, filed March 26, 2015 (now pending). The content and disclosure of the foregoing application
5 are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

The transforming growth factor- β (TGF β) superfamily contains a variety of growth factors that share common sequence elements and structural motifs. These proteins are known to exert biological effects on a large variety of cell types in both vertebrates and
10 invertebrates. Members of the superfamily perform important functions during embryonic development in pattern formation and tissue specification and can influence a variety of differentiation processes, including adipogenesis, myogenesis, chondrogenesis, cardiogenesis, hematopoiesis, neurogenesis, and epithelial cell differentiation. Superfamily members have diverse, often complementary effects. By manipulating the activity of a
15 member of the TGF β family, it is often possible to cause significant physiological changes in an organism. Changes in muscle, bone, cartilage and other tissues may be achieved by increasing or antagonizing signaling that is mediated by an appropriate TGF β superfamily member.

Naturally occurring proteins often referred to as ligand traps function as extracellular
20 regulators of TGF β superfamily ligands. Such ligand traps act either in soluble form or attached to the extracellular matrix and typically sequester ligand by binding to epitopes required for receptor activation. One family of ligand traps includes follistatin and follistatin-related proteins, which possess desirable functional activity based on multiple lines of evidence but have proven difficult to use as therapeutic agents. Thus, there is a need for such
25 agents that function as potent regulators of TGF β superfamily signaling.

SUMMARY OF THE INVENTION

In part, the disclosure provides heteromeric protein complexes that comprise a
follistatin-related fusion protein. Such heteromeric protein complexes optionally exhibit high
30 affinity binding and inhibition of ligands, such as activin A, activin B, activin C, activin E,

GDF8, and GDF11, and, optionally, exhibit improved production in recombinant cell lines, improved properties for purification and/or extended serum half-life relative to native forms of follistatin-related proteins.

In certain aspects, protein complexes described herein comprise a first polypeptide
5 covalently or non-covalently associated with a second polypeptide wherein the first polypeptide comprises the amino acid sequence of a follistatin-related polypeptide and the amino acid sequence of a first member of an interaction pair and the second polypeptide comprises the amino acid sequence of a second member of the interaction pair. In other aspects, protein complexes described herein comprise a first polypeptide non-covalently
10 associated with a second polypeptide wherein the first polypeptide comprises the amino acid sequence of a follistatin-related polypeptide and the amino acid sequence of a first member of an interaction pair and the second polypeptide comprises the amino acid sequence of a second member of the interaction pair.

Follistatin-related polypeptides described herein include polypeptides comprising,
15 consisting essentially of, or consisting of an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to any one of SEQ ID Nos: 1-33. Optionally, the follistatin-related polypeptide is connected directly to the first member of the interaction pair, or an intervening sequence, such as a linker, may be positioned between the amino acid sequence of the follistatin-related polypeptide and the amino acid
20 sequence of the first member of the interaction pair. Examples of linkers include the sequences TGGG, TGGGG, SGGGG, GGGGS, and GGG. Optionally, the first polypeptide may comprise additional amino acids (*e.g.*, 1-50, 1-40, 1-30, 1-20, or 1-10 amino acids) positioned C-terminal and/or N-terminal to the first member of the interaction pair or the follistatin-related polypeptide. Such additional amino acids positioned C-terminal or N-
25 terminal to the first member of the interaction pair or the follistatin-related polypeptide may confer a biological activity. Alternatively, such additional amino acids may confer no, or substantially no, biological activity. Optionally, such additional amino acids are heterologous to the follistatin-related polypeptide and preferably are not a follistatin-related polypeptide.

The second polypeptide may consist essentially of or consist of the second member of
30 the interaction pair. Optionally, the second polypeptide may comprise additional amino acids (*e.g.*, 1-50, 1-40, 1-30, 1-20, or 1-10 amino acids) positioned C-terminal and/or N-terminal to the second member of the interaction pair. Such additional amino acids positioned C-terminal or N-terminal to the second member of the interaction pair may confer a biological activity. Alternatively, such additional amino acids positioned C-terminal or N-terminal to

the second member of the interaction pair may confer no, or substantially no, biological activity. Optionally, such additional amino acids positioned C-terminal or N-terminal to the second member of the interaction pair should be heterologous to the follistatin-related polypeptide and preferably are not a follistatin-related polypeptide.

5 Interaction pairs described herein are designed to promote dimerization or form higher order multimers. In some embodiments, the interaction pair may be any two polypeptide sequences that interact to form a complex, particularly a heterodimeric complex although operative embodiments may also employ an interaction pair that forms a homodimeric complex. The first and second members of the interaction pair may be an
10 asymmetric pair, meaning that the members of the pair preferentially associate with each other rather than self-associating. Accordingly, first and second members of an asymmetric interaction pair may associate to form a heterodimeric complex. Alternatively, the interaction pair may be unguided, meaning that the members of the pair may associate with each other or self-associate without substantial preference and thus may have the same or different amino
15 acid sequences. Accordingly, first and second members of an unguided interaction pair may associate to form a homodimeric complex or a heterodimeric complex. Optionally, the first member of the interaction action pair (*e.g.*, an asymmetric pair or an unguided interaction pair) associates covalently with the second member of the interaction pair. Optionally, the first member of the interaction action pair (*e.g.*, an asymmetric pair or an unguided
20 interaction pair) associates non-covalently with the second member of the interaction pair.

Traditional Fc fusion proteins and antibodies are examples of unguided interaction pairs, whereas a variety of engineered Fc domains have been designed as asymmetric interaction pairs. Therefore, a first member and/or a second member an interaction pair described herein may comprise a constant domain of an immunoglobulin, including, for
25 example, the Fc portion of an immunoglobulin. Optionally, a first member of an interaction pair may comprise an amino acid sequence that is derived from an Fc domain of an IgG1, IgG2, IgG3, or IgG4 immunoglobulin of a mammal, preferably a human. For example, the first member of an interaction pair may comprise, consists essentially of, or consist of an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
30 98%, 99% or 100% to any one of SEQ ID Nos: 34-46. Optionally, a second member of an interaction pair may comprise an amino acid sequence that is derived from an Fc domain of an IgG1, IgG2, IgG3, or IgG4. For example, the second member of an interaction pair may comprise, consists essentially of, or consist of an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% to any one of SEQ

ID Nos: 34-46. In some embodiments, a first member and a second member of an interaction pair comprise Fc domains derived from the same immunoglobulin class and subtype. In other embodiments, a first member and a second member of an interaction pair comprise Fc domains derived from different immunoglobulin classes or subtypes. Optionally, a first member and/or a second member of an interaction pair (*e.g.*, an asymmetric pair or an unguided interaction pair) comprise a modified constant domain of an immunoglobulin, including, for example, a modified Fc portion of an immunoglobulin. For example, protein complexes of the disclosure may comprise a first modified Fc portion of an IgG comprising an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group: SEQ ID Nos 34-46 and a second modified Fc portion of an IgG, which may be the same or different from the amino acid sequence of the first modified Fc portion of the IgG, comprising an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group: SEQ ID Nos 34-46.

In some embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 39 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 40. In other embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 40 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 39.

In some embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 41 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 42. In other embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 42 and, optionally, the second member of the interaction pair comprises an

amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 41.

In some embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44. In other embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43.

In some embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 45 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 46. In other embodiments, the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 46 and, optionally, the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 45.

In some embodiments, the disclosure provides a fusion polypeptide comprising an amino acid sequence of a follistatin-related polypeptide and the amino acid sequence of a member of an asymmetric interaction pair. Such fusion proteins may comprise a follistatin-related polypeptide comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any of SEQ ID Nos: 1-33. Optionally, the fusion polypeptide may comprise a linker polypeptide positioned between the amino acid sequence of the follistatin-related polypeptide and the amino acid sequence of the member of the asymmetric interaction pair. In certain embodiments, the member of the asymmetric interaction pair comprises a constant domain of an immunoglobulin such as an Fc domain of an immunoglobulin. For example, follistatin-related polypeptide fusion

proteins of the disclosure may comprise an asymmetric interaction pair that comprises an amino acid sequence that is derived from an Fc domain of an IgG1, IgG2, IgG3 or IgG4. In some embodiments, the asymmetric interaction pair of the fusion protein comprises, consists essentially of, or consists of an amino acid sequence that is at least 80%, 85%, 90%, 95%, 5 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 34-46. In some embodiments, the member of the asymmetric interaction pair of the fusion protein comprises, consists essentially of, or consists of an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 39-46.

Preferably protein complexes of the disclosure bind to one or more ligands selected 10 from the group consisting of: GDF8, GDF-11, activin A, activin B, activin C, or activin E. Optionally, protein complexes of the disclosure bind to one or more of these ligands with a K_D of greater than or equal to 10^{-8} , 10^{-9} , 10^{-10} , 10^{-11} , or 10^{-12} . In some embodiments, protein complexes of the disclosure may inhibit signaling (*e.g.*, signaling by SMADs 1, 2, 3, 5, and/or 8) by one or more ligands selected from the group consisting of: GDF8, GDF-11, 15 activin A, activin B, activin C, or activin E. Optionally, protein complexes of the disclosure may inhibit signaling (*e.g.*, signaling by SMADs 1, 2, 3, 5, and/or 8) by one or more of these ligands as measured in a cell-based assay.

Optionally, protein complexes of the disclosure exhibit improved purification compared to native, monomeric follistatin-related peptides. Optionally protein complexes of 20 the disclosure exhibit a serum half-life of at least 4, 6, 12, 24, 36, 48, or 72 hours in a mammal (*e.g.*, a mouse or a human). Optionally, protein complexes of the disclosure may exhibit a serum half-life of at least 6, 8, 10, 12, 14, 20, 25, or 30 days in a mammal (*e.g.*, a mouse or a human).

In certain aspects the disclosure provides nucleic acids encoding any of the first 25 and/or second polypeptides disclosed herein. Nucleic acids disclosed herein may be operably linked to a promoter for expression, and the disclosure further provides cells transformed with such recombinant polynucleotides. Preferably the cell is a mammalian cell such as a COS cell or a CHO cell.

In certain aspects, the disclosure provides methods for making any of the first and 30 second polypeptides disclosed herein as well as protein complexes comprising such a first and second polypeptide of the disclosure. Such a method may include expressing any of the nucleic acids disclosed herein in a suitable cell (*e.g.*, CHO cell or a COS cell). Such a method may comprise: a) culturing a cell under conditions suitable for expression of the first and/or second polypeptide of the disclosure, wherein said cell is transformed with a first

and/or second polypeptide expression construct; and b) recovering the first and/or second polypeptide so expressed. Similarly, a method may comprise: a) culturing a cell under conditions suitable for expression of the first and second polypeptide of the disclosure, wherein said cell is transformed with a first and second polypeptide expression construct; and
5 b) recovering the protein complex of the disclosure so expressed. First and/or second polypeptides described herein, as well as protein complex comprising first and second polypeptides of the disclosure, may be recovered as crude, partially purified, or highly purified fractions using any of the well-known techniques for obtaining protein from cell cultures.

10 Any of the protein complexes described herein may be incorporated into a pharmaceutical preparation. Optionally, such pharmaceutical preparations are at least 80%, 85%, 90%, 95%, 97%, 98% or 99% pure with respect to other polypeptide components. In some embodiments, pharmaceutical preparation described herein comprises less than 20%, 15%, 10%, 5%, 3%, 2%, or 1% of homodimers formed by the self-association of the first or
15 second polypeptides. Optionally, pharmaceutical preparations disclosed herein may comprise one or more additional active agents.

In certain aspects, compositions of the present disclosure, including for example various protein complexes comprising follistatin-related fusion polypeptides disclosed herein, can be used for treating or preventing a disease or condition that is associated with abnormal
20 activity of a follistatin-related fusion polypeptide and/or a follistatin ligand (*e.g.*, myostatin, activins, GDF11). These diseases, disorders or conditions are generally referred to herein as “follistatin-associated conditions.” In certain embodiments, the present disclosure provides methods of treating or preventing an individual in need thereof through administering to the individual a therapeutically effective amount of a protein complex described herein. These
25 methods are particularly aimed at therapeutic and prophylactic treatments of animals, and more particularly, humans.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows multiple sequence alignment of Fc domains from human IgG isotypes
30 using Clustal 2.1. Hinge regions are indicated by dotted underline. Double underline indicates examples of positions that may be engineered in IgG1 Fc (SEQ ID NO: 34) to promote asymmetric chain pairing and the corresponding positions with respect to other isotypes (SEQ ID NOS: 35, 36, 38).

Figure 2 shows a schematic example of a heteromeric protein complex comprising a follistatin-related polypeptide for therapeutic use. The “follistatin-related polypeptide” (A) may be positioned C-terminal to, or N-terminal to, the “first member of an interaction pair” (B). A linker, as well as other amino acid sequences, may be positioned between the
5 follistatin-related polypeptide and the first member of an interaction pair. The first and second members of the interaction pair (B, C) may be an asymmetric pair, meaning that the members of the pair preferentially associate with each other rather than self-associate, or the interaction pair may be unguided, meaning that the members of the pair may associate with each other or self-associate without substantial preference, and may have the same or
10 different amino acid sequences. Traditional Fc fusion proteins and antibodies are examples of unguided interaction pairs, whereas a variety of engineered Fc domains have been designed as asymmetric interaction pairs. In the second polypeptide, additional amino acids may be positioned C-terminal or N-terminal to the second member of the interaction pair, and such amino acids may or may not confer a biological activity but should be heterologous to
15 the follistatin-related polypeptide and preferably are not a follistatin-related polypeptide.

DETAILED DESCRIPTION OF THE INVENTION

1. Overview

A. Regulation of tissue homeostasis by TGF β superfamily ligands

20 TGF β superfamily signaling pathways are critical for prenatal and postnatal regulation of diverse cell types and tissues, including muscle, bone, adipose tissue, pancreatic function, hematopoietic cells, and others. Protein complexes described herein may bind to one or more ligands of the TGF β superfamily, including for example a member of the activin group, the Growth and Differentiation Factor (GDF) group, the Bone Morphogenetic Protein (BMP)
25 group or one or more other members of the superfamily. The superfamily ligand myostatin, encoded by the *MSTN* gene and also known as growth differentiation factor-8 (GDF8), is widely recognized as an endogenous inhibitor of skeletal muscle mass. Mice homozygous for a deletion of *Mstn* display robust increases in skeletal muscle mass due to a combination of increased fiber number and muscle fiber hypertrophy [McPherron et al. (1997) Nature
30 387:83-90]. Selective postnatal loss of myostatin signaling causes significant muscle fiber hypertrophy, thereby indicating that myostatin is an important regulator of muscle homeostasis in adults [Lee et al. (2010) Mol Endocrinol 24:1998-2008]. Naturally occurring

mutations of myostatin are associated with increased skeletal muscle mass in humans, cattle, sheep, and dogs. For example, the Piedmontese and Belgian Blue cattle breeds carry a loss-of-function mutation in *MSTN* that causes a marked increase in muscle mass [Grobet et al. (1997) Nat Genet 17:71-74]. In humans, inactive alleles of *MSTN* are associated with
5 increased muscle mass and, reportedly, exceptional strength [Schuelke et al (2004) N Engl J Med 2004, 350:2682-8.] Conversely, muscle wasting in humans associated with infection by human immunodeficiency virus is accompanied by increased *MSTN* expression [Gonzalez-Cadavid et al. (1998) Proc Natl Acad Sci USA 95:14938-14943].

Inhibition of myostatin activity may be an effective strategy for increasing muscle
10 mass and strength in patients with inherited and acquired clinical conditions associated with debilitating muscle loss [Lee (2004) Annu Rev Cell Dev Biol 20:61-86; Tsuchida (2008) Curr Opin Drug Discov Dev 11:487-494; Rodino-Klapac et al. (2009) Muscle Nerve 39:283-296]. Studies with mouse models of muscle disease have suggested that loss of myostatin signaling has beneficial effects in a wide range of disease settings, including muscular
15 dystrophy, spinal muscular atrophy, cachexia, steroid-induced myopathy, and age-related sarcopenia. Moreover, loss of myostatin signaling has been shown to decrease fat accumulation and improve glucose metabolism in models of metabolic diseases, raising the possibility that targeting myostatin may also have applications for diseases such as obesity and type 2 diabetes. Thus there is considerable interest in identifying methods for therapeutic
20 inhibition of myostatin signaling in vivo.

Like other superfamily ligands, myostatin is synthesized as a precursor consisting of a signal peptide, an N-terminal prodomain, and a C-terminal mature domain. During synthesis, the myostatin prodomain interacts noncovalently with mature myostatin to maintain these
25 molecules in a conformation that facilitates dimerization [Harrison et al (2011) Growth Factors 29:174-186]. After cleavage of the dimeric precursor, the twin prodomains initially remain attached to the mature protein, forming a latent complex [(Miyazono et al (1988) J Biol Chem 263:6407-6415; Wakefield et al (1988) J Biol Chem 263:7646-7654; Brown et al (1990) Growth Factors 3:35-43]. To a greater degree than most TGF β ligands, secreted myostatin initially exists in a latent or semilantent form whose activity can then be unmasked
30 by other factors [Wolfman et al (2003) Proc Natl Acad Sci USA 100:15842-15846; Szlama et al (2013) FEBS J 280:3822-3839]. Latent myostatin resides in the extracellular space, where the prodomain interacts with matrix proteins to regulate myostatin bioavailability [Anderson et al (2008) J Biol Chem 283:7027-7035; Sengle et al (2011) J Biol Chem 286:5087-5099], or

enters the circulation, where the majority of myostatin exists in this latent form [Hill et al (2002) *J Biol Chem* 277:40735-40741]. In the extracellular compartment, interaction of the myostatin prodomain with the proteoglycan perlecan increases concentrations of the latent complex near target cells. Latent myostatin is converted to an active form by site-specific
5 cleavage of one or both associated prodomains by metalloproteases located in the extracellular matrix [Wolfman et al (2003) *Proc Natl Acad Sci USA* 100:15842-15846].

Once released from its prodomain, myostatin exerts its cellular effects by inducing formation of ternary complexes incorporating an activin type II receptor (ActRIIA or ActRIIB) and an activin type I receptor (generally ALK4 or ALK7). These activated receptor
10 complexes in turn phosphorylate Smad proteins (Smad2 and Smad3, Smad2/3), which enables the Smad proteins to form a transcriptional complex with Smad4 that regulates expression of specific target genes [see, e.g., Mathews and Vale (1991) *Cell* 65:973-982; Attisano et al. (1992) *Cell* 68: 97-108; Massagué (2000) *Nat. Rev. Mol. Cell Biol.* 1:169-178]. Type I and type II receptors are transmembrane proteins, composed of a ligand-binding
15 extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type II receptors are required for binding ligands, while type I receptors are essential for signaling.

Although myostatin is the best established case, one or more additional ligands that signal through ActRIIA and/or ActRIIB have also been implicated as endogenous inhibitors
20 of muscle hypertrophy [Lee et al (2005) *Proc Natl Acad Sci USA* 102:18117-18122]. Activins are a family of dimeric ligands within the TGF β superfamily and are composed of inhibin- β subunits. Specifically, activins include the homodimeric forms activin A ($\beta_A\beta_A$), activin B ($\beta_B\beta_B$), activin C ($\beta_C\beta_C$), and activin E ($\beta_E\beta_E$), as well as heterodimeric forms, including activin AB ($\beta_A\beta_B$) and heterodimers containing β_C or β_E . In addition, the
25 structurally related heterodimer inhibin is an important inhibitory regulator of activin signaling in various tissues.

Activins play diverse physiologic and pathologic roles. Multiple lines of evidence implicate activins as functioning in concert with myostatin to limit muscle mass, and activin antagonists can promote muscle growth or counteract muscle loss in vivo. [Link et al (1997)
30 *Exp Cell Res* 233:350-362; He et al (2005) *Anat Embryol (Berl)* 209:401-407; Souza et al (2008) *Mol Endocrinol* 22:2689-2702; Gilson et al (2009) *Am J Physiol Endocrinol Metab* 297:E157-E164; Lee et al (2010) *Mol Endocrinol* 24:1998-2008; Zhou et al. (2010) *Cell* 142:531-43]. Activins play a major role in bone homeostasis and are implicated as regulators

of erythropoiesis [Maguer-Satta et al (2003) *Exp Cell Res* 282:110-120; Fields et al (2013) *Expert Opin Investig Drugs* 22:87-101]. Recent studies have pointed to roles of activins in wound healing, angiogenesis, inflammation, immunity, fibrosis, and cancer [Antsiferova et al (2012) *J Cell Sci* 125:3929-3937]. The activin/inhibin signaling pathway is associated with cancer of the ovaries, testes, and adrenal glands. In addition, activin A is a major inhibitory regulator of hepatocyte proliferation, and dysregulated activin signaling has been implicated in hepatic diseases including inflammation, fibrosis, liver failure, and cancer. [Kreidl et al (2009) *World J Hepatol* 1:17-27]. Other functions of activins include induction of mesodermal differentiation, modulation of the cell cycle, support of neuronal cell survival, and coordination of endocrine cell activity [DePaolo et al. (1991) *Proc Soc Exp Biol Med* 198:500-512; Dyson et al (1997) *Curr Biol* 7:81-84; Woodruff (1998) *Biochem Pharmacol* 55:953-963].

As described herein, agents that bind to “activin A” are agents that specifically bind to the β_A subunit, whether in the context of an isolated β_A subunit or as a dimeric complex (*e.g.*, a $\beta_A\beta_A$ homodimer or a $\beta_A\beta_B$ heterodimer). In the case of a heterodimer complex (*e.g.*, a $\beta_A\beta_B$ heterodimer), agents that bind to “activin A” are specific for epitopes present within the β_A subunit, but do not bind to epitopes present within the non- β_A subunit of the complex (*e.g.*, the β_B subunit of the complex). Similarly, agents disclosed herein that antagonize (inhibit) “activin A” are agents that inhibit one or more activities as mediated by a β_A subunit, whether in the context of an isolated β_A subunit or as a dimeric complex (*e.g.*, a $\beta_A\beta_A$ homodimer or a $\beta_A\beta_B$ heterodimer). In the case of $\beta_A\beta_B$ heterodimers, agents that inhibit “activin A” are agents that specifically inhibit one or more activities of the β_A subunit, but do not inhibit the activity of the non- β_A subunit of the complex (*e.g.*, the β_B subunit of the complex). This principle applies also to agents that *bind to* and/or *inhibit* “activin B”, “activin C”, and “activin E”. Agents disclosed herein that antagonize “activin AB” are agents that inhibit one or more activities as mediated by the β_A subunit and one or more activities as mediated by the β_B subunit.

Growth differentiation factor-11 (GDF11), also known as bone morphogenetic protein-11 (BMP11), is expressed in the tail bud, limb bud, maxillary and mandibular arches, and dorsal root ganglia during mouse development [see, *e.g.*, Nakashima et al. (1999) *Mech. Dev.* 80: 185-189]. GDF11 plays a unique role in patterning both mesodermal and neural tissues [see, *e.g.*, Gamer et al. (1999) *Dev Biol.*, 208:222-32] and is a negative regulator of chondrogenesis and myogenesis in developing chick limb [see, *e.g.*, Gamer et al. (2001) *Dev*

Biol. 229:407-20]. Expression of GDF11 in brain suggests that GDF11 may also regulate neural activity, and GDF11 inhibits neurogenesis in the olfactory epithelium [see, e.g., Wu et al. (2003) *Neuron*. 37:197-207]. Recent studies implicate GDF11 as an important regulatory signal in erythropoiesis, particularly during late-stage erythroid differentiation [Suragani et al. (2014) *Nat Med* 20:408-414]. In addition, GDF11 has been investigated as a potential inhibitor of muscle hypertrophy based on structural similarity to myostatin, shared signaling components, and GDF11 expression in skeletal muscle [McPherron et al. (1999) *Nat. Genet.* 22: 260-264]. Although GDF11, like myostatin, is detectable in the general circulation in a latent complex with its prodomain and inhibits muscle cell differentiation *ex vivo* [Souza et al. (2008) *Mol Endocrinol* 22:2689-2702], genetic studies have not revealed a role for GDF11 in regulating muscle size, fiber number, or fiber type, even under conditions of myostatin deficiency [McPherron et al. (2009) *BMC Devel Biol* 9:24]. Thus, it remains to be firmly determined whether GDF11 contributes to the regulation of muscle mass.

15 **B. Extracellular inhibitors of TGF β superfamily ligands**

In addition to the ligand-associated prodomains discussed above, several other native proteins inhibit TGF β superfamily ligands extracellularly and thereby regulate the activity of these ligands in critical ways. In humans, soluble endogenous inhibitors of myostatin, activins, and GDF11 include multiple follistatin isoforms, the product of the follistatin-like gene (FSTL3) known as FLRG, and a pair of closely related proteins named WFIKKN1 and WFIKKN2 based on their shared domain structure which includes a whey acidic protein domain (W), a follistatin-Kazal domain (F), an immunoglobulin domain (I), two tandem domains related to Kunitz-type protease inhibitor modules (KK), and a netrin domain (N). Follistatin, FLRG, WFIKKN1, and WFIKKN2 polypeptides each contain one or more structural motifs generally referred to as “follistatin domains” which are important for selective binding to TGF β superfamily ligands. Therefore, as disclosed herein, the term “follistatin-related polypeptides” includes, for example, native follistatin, FLRG, WFIKKN1, and WFIKKN2 sequences, as well as variants and truncations thereof.

Best studied among extracellular inhibitors of myostatin, activins, and/or GDF11 is follistatin, a single gene (*FST*) from which are generated multiple isoforms. Follistatin is an autocrine glycoprotein expressed in nearly all tissues of higher animals. It was initially isolated from follicular fluid and was identified as a protein fraction that inhibited follicle-

stimulating hormone (FSH) secretion from the anterior pituitary [Esch et al. (1987) *Mol Endocrinol* 1:849-855]. The importance of follistatin in TGF β superfamily signaling is illustrated by the multiple defects and perinatal death observed in follistatin-deficient mice [Matzuk et al (1995) *Nature* 374:360-363]. Postnatally, follistatin promotes muscle growth by inhibiting myostatin and activins [Lee et al (2010) *Mol Endocrinol* 24:1998-2008] and potentially GDF11. The biologic activity of follistatin stems from its ability to bind these ligands with high affinity and thereby prevent interaction of the ligand with its cell-surface receptor – ActRIIA or ActRIIB [Nakamura et al (1990) *Science* 247:836-838; Kogawa et al (1991) *Endocrinology* 128:1434-1440; Schneyer et al (1994) *Endocrinology* 135:667-674; de Winter et al (1996) *Mol Cell Endocrinol* 116:105-114; Thompson et al (2005) *Dev Cell* 9:535-543]. In addition, follistatin contains a heparin-binding domain that in some isoforms facilitates follistatin interaction with proteoglycans at the cell surface [Inouye et al (1992) *Mol Cell Endocrinol* 90:1-6], thereby maintaining higher concentrations of follistatin near the sites of ligand action. Furthermore, binding of follistatin (FST288) to myostatin substantially increases the affinity of follistatin for heparin [Cash et al (2009) *EMBO J* 28:2662-2676], thereby suggesting that ligand binding promotes cell-surface localization of the follistatin-myostatin complex.

Follistatin contains three repeats of a distinctive structural motif known as a “follistatin domain”, which encompasses a conserved linear pattern of ten cysteines and forms a characteristic arrangement of intramolecular disulfide bonds [Esch et al. (1987) *Mol Endocrinol* 1:849-855]. A follistatin domain is defined herein as an amino acid domain, or a nucleic acid sequence encoding an amino acid domain, characterized by cysteine-rich repeats. A follistatin domain typically encompasses a span of 65-90 amino acids and contains ten conserved cysteine residues and a region similar to Kazal serine protease inhibitor domains. Thus, follistatin domains are sometimes referred to as “follistatin/Kazal domains” or “follistatin/Kazal-like domains”. In general, the loop regions between the cysteine residues exhibit sequence variability, but some conservation is present. The loop between the fourth and fifth cysteines is usually short, containing only one or two amino acids. The amino acids in the loop between the seventh and eighth cysteines are generally the most highly conserved, containing a consensus sequence of (G,A)-(S,N)-(S,N,T)-(D,N)-(G,N) followed by a (T,S)-Y motif. The region between the ninth and tenth cysteines generally contains a motif incorporating two hydrophobic residues (specifically V, I, or L) separated by another amino acid.

The term “follistatin polypeptide” is used to refer to polypeptides comprising any naturally occurring polypeptide of the follistatin family as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity, including, for example, ligand binding (e.g., myostatin, GDF11, activin A, activin B). For example, follistatin polypeptides include polypeptides comprising an amino acid sequence derived from the sequence of any known follistatin having a sequence at least about 80% identical to the sequence of a follistatin polypeptide (SEQ ID NOs: 1-17), and preferably at least 85%, 90%, 95%, 97%, 99% or greater identity to any of SEQ ID NOs: 1-17. The term “follistatin fusion polypeptide” may refer to fusion proteins that comprise any of the polypeptides mentioned above along with a heterologous (non-follistatin) portion. An amino acid sequence is understood to be heterologous to follistatin if it is not uniquely found in the long (315 amino acid) form of human follistatin, represented by SEQ ID NO:3. Many examples of heterologous portions are provided herein, and such heterologous portions may be immediately adjacent, by amino acid sequence, to the follistatin polypeptide portion of a fusion protein, or separated by intervening amino acid sequence, such as a linker or other sequence. In addition, methods for making and testing libraries of polypeptides are described herein and such methods also pertain to making and testing variants of follistatin.

Follistatin is a single-chain polypeptide with a range of molecular weights from 31 to 49 kDa based on alternative mRNA splicing and variable glycosylation of the protein. Alternatively spliced mRNAs from the follistatin gene encode isoforms of 288 amino acids (i.e., FST288) and 315 amino acids (i.e., FST315), and the latter can be processed proteolytically to yield yet another isoform, follistatin 303 (FST303). Analysis of the amino acid sequence of native human follistatin polypeptide has revealed that it comprises five domains: a signal sequence (amino acids 1-29 of SEQ ID NO:1), an N-terminal domain (FST_{ND}) (amino acids 30-94 of SEQ ID NO:1), follistatin domain-1 (FST_{FD1}) (amino acids 95-164 of SEQ ID NO:1), follistatin domain-2 (FST_{FD2}) (amino acids 168-239 of SEQ ID NO:1), and follistatin domain-3 (FST_{FD3}) (amino acids 245-316 of SEQ ID NO:1). See Shimanski et al (1988) Proc Natl Acad Sci USA 85:4218-4222.

The human follistatin-288 (FST288) precursor has the following amino acid sequence (SEQ ID NO: 1) (NCBI Reference Sequence NP_006341; Uniprot P19883-2), with the signal peptide indicated by dotted underline, the N-terminal domain (FST_{ND}) indicated by dashed underline, and the follistatin domains 1-3 (FST_{FD1}, FST_{FD2}, FST_{FD3}) indicated by solid underline.

1 MVRARHQPGG LCLLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL
 51 SKEECCSTGR LSTSWTEEDV NDNTLFLKWMI FNGGAPNCIP CKETCENVDC
 101 GPGKKCRMNK KNKPRVCAP DCSNITWKGP VCGLDGKTYR NECALLKARC
 151 KEQPELEVQY QGRCKKTCRD VFCPGSSTCV VDQTNNAYCV TCNRICPEPA
 5 201 SSEQYLCGND GVTYSSACHL RKATCLLGRS IGLAYEGKCI KAKSCEDIQC
 251 TGGKKCLWDF KVGRGRCSLC DELCPDSKSD EPVCASDNAT YASECAMKEA
 301 ACSSGVLLEV KHSGSCN (SEQ ID NO:1)

The mature (processed) human follistatin variant FST288 has the following amino acid sequence (SEQ ID NO: 2) with the N-terminal domain indicated by dashed underline and the follistatin domains 1-3 indicated by solid underline. Moreover, it will be appreciated that any of the initial amino acids G or N, prior to the first cysteine may be removed by processing or intentionally eliminated without any consequence, and polypeptides comprising such slightly smaller polypeptides are further included.

1 GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLFLKWM
 15 51 IFNGGAPNCI PCKETCENVD CGPGKKCRMN KKNKPRVCA PDCSNITWKG
 101 PVCGLDGKTY RNECALLKAR CKEQPELEVQ YQGRCKKTCR DVFCPGSSTC
 151 VVDQTNNAYC VTCNRICPEP ASSEQYLCGN DGVTYSSACH LRKATCLLGR
 201 SIGLAYEGKC IKAKSCEDIQ CTGGKKCLWD FKVGRGRCSL CDELCPDSKS
 251 DEPVCASDNA TYASECAMKE AACSSGVLLE VKHSGSCN (SEQ ID NO:2)

The human follistatin-315 (FST315) precursor has the following amino acid sequence (SEQ ID NO: 3) (NCBI Reference Sequence NP_037541.1; Uniprot P19883), with the signal peptide indicated by dotted underline, the N-terminal domain (FST_{ND}) indicated by dashed underline, and the follistatin domains 1-3 (FST_{FD1}, FST_{FD2}, FST_{FD3}) indicated by solid underline.

25 1 MVRARHQPGG LCLLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL
 51 SKEECCSTGR LSTSWTEEDV NDNTLFLKWMI FNGGAPNCIP CKETCENVDC
 101 GPGKKCRMNK KNKPRVCAP DCSNITWKGP VCGLDGKTYR NECALLKARC
 151 KEQPELEVQY QGRCKKTCRD VFCPGSSTCV VDQTNNAYCV TCNRICPEPA
 201 SSEQYLCGND GVTYSSACHL RKATCLLGRS IGLAYEGKCI KAKSCEDIQC
 30 251 TGGKKCLWDF KVGRGRCSLC DELCPDSKSD EPVCASDNAT YASECAMKEA
 301 ACSSGVLLEV KHSGSCNSIS EDTEEEEEDE DQDYSFPISS ILEW
 (SEQ ID NO:3)

Mature (processed) human FST315 has the following amino acid sequence (SEQ ID NO: 4) with the N-terminal domain indicated by dashed underline and the follistatin domains

1-3 indicated by solid underline. Moreover, it will be appreciated that any of the initial amino acids G or N, prior to the first cysteine may be removed by processing or intentionally eliminated without any consequence, and polypeptides comprising such slightly shorter polypeptides are further included.

```

5      1  GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLTKWM
      51  IFNGGAPNCI PKETCENVD CGPGKKCRMN KKNKPRCVCA PDCSNITWKG
     101  PVCGLDGKTY RNECALLKAR CKEQPELEVQ YQGRCKKTCR DVFCPGSSTC
     151  VVDQTNNAYC VTCNRICPEP ASSEQYLCGN DGVTYSSACH LRKATCLLGR
     201  SIGLAYEGKC IKAKSCEDIQ CTGGKKCLWD FKVGRGRCSL CDELCPDSKS
10     251  DEPVCASDNA TYASECAMKE AACSSGVLE VKHSGSCNSI SEDTEEEED
      301  EDQDYSFPIS SILEW      (SEQ ID NO:4)

```

Follistatin-related polypeptides of the disclosure may include any naturally occurring domain of a follistatin protein as well as variants thereof (e.g., mutants, fragments, and peptidomimetic forms) that retain a useful activity. For example, it is well-known that FST315 and FST288 have high affinity for myostatin, activins (activin A and activin B), and GDF11 and that the follistatin domains (e.g., FST_{ND}, FST_{FD1}, FST_{FD2}, and FST_{FD3}) are thought to be involved in the binding of such TGF β ligands. However, there is evidence that each of these four domains has a different affinity for these TGF- β ligands. For example, a recent study has demonstrated that polypeptide constructs comprising only the N-terminal domain and two FST_{FD1} domains in tandem retained high affinity for myostatin, demonstrated little or no affinity for activins, and promoted systemic muscle growth when introduced into a mouse by gene expression [Nakatani et al (2008) FASEB 22:478-487]. Accordingly, the present disclosure encompasses, in part, variant follistatin proteins that demonstrate selective binding and/or inhibition of a given TGF β ligand relative to the naturally occurring FST protein (e.g., maintaining high-affinity for myostatin while having a significantly reduced affinity for activin).

In certain aspects, the disclosure includes polypeptides comprising the FST_{ND} domain, as set forth below (SEQ ID NO: 5), and, for example, one or more heterologous polypeptides, and moreover, it will be appreciated that any of the initial amino acids G or N, prior to the first cysteine may be deleted, as in the example shown below (SEQ ID NO: 6).

```

      1  GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLTKWM
     51  IFNGGAPNCI PKET      (SEQ ID NO: 5)

      1  CWLRQAKNGR CQVLYKTELS KEECCSTGRL STSWTEEDVN DNTLTKWMIF
     51  NGGAPNCIPC KET      (SEQ ID NO: 6)

```

In certain aspects, the disclosure includes polypeptides comprising the FST_{FD1} domain (SEQ ID NO: 7) which contains the minimal core activities of myostatin (and/or GDF11) binding along with heparin binding as set forth below, and, for example, one or more heterologous polypeptides.

5 1 CENVDCGPGK KCRMNKKKPK RCVCAPDCSN ITWKGVCGL DGKTYRNECA
51 LLKARCKEQP ELEVVQYQGR (SEQ ID NO: 7)

In certain aspects, the disclosure includes polypeptides comprising the FST_{FD2} domain (SEQ ID NO: 8) and/or the FST_{FD3} domain (SEQ ID NO: 9) as set forth below, and, for example, one or more heterologous polypeptides.

10 1 CRDVFCPGSS TCVVDQTNNA YCVTCNRICP EPASSEQYLC GNDGVITYSSA
51 CHLRKATCLL GRSIGLAYEG KC (SEQ ID NO: 8)

1 CEDIQCTGGK KCLWDFKVGR GRCSLCDEL C PDSKSDEPVC ASDNATYASE
51 CAMKEAACSS GVLLEVKHSG SC (SEQ ID NO: 9)

An FST_{FD1} sequence may be advantageously maintained in structural context by
15 expression as a polypeptide further comprising the FST_{ND} domain. Accordingly, the disclosure includes polypeptides comprising the FST_{ND}-FST_{FD1} sequence, as set forth below (SEQ ID NO:10), and, for example, one or more heterologous polypeptides, and moreover, it will be appreciated that any of the initial amino acids G or N, prior to the first cysteine may be removed by processing or intentionally eliminated without any consequence, and
20 polypeptides comprising such slightly shorter polypeptides are further included.

1 CWLROAKNGR CQVLYKTELS KEECCSTGRL STSWTEEDVN DNTLFKWMIF
51 NGGAPNCIPC KETCENVDCG PGKKCRMNKK NKPRVCAPD CSNITWKGVP
101 CGLDGKTYRN ECALLKARCK EQPELEVQYQ GRC (SEQ ID NO: 10)

As demonstrated by Nakatani et al., a FST_{ND}-FST_{FD1}-FST_{FD1} construct is sufficient to
25 confer systemic muscle growth when genetically expressed in a mouse, and accordingly the disclosure includes polypeptides comprising the amino acid sequence below (SEQ ID NO: 11) and, for example, one or more heterologous polypeptides.

1 CWLROAKNGR CQVLYKTELS KEECCSTGRL STSWTEEDVN DNTLFKWMIF
51 NGGAPNCIPC KETCENVDCG PGKKCRMNKK NKPRVCAPD CSNITWKGVP
30 101 CGLDGKTYRN ECALLKARCK EQPELEVQYQ GRCCENVDCG PGKKCRMNKK
151 NKPRVCAPD CSNITWKGVP CGLDGKTYRN ECALLKARCK EQPELEVQYQ
201 GRC (SEQ ID NO: 11)

While the FST_{FD1} sequence confers myostatin and GDF11 binding, it has been demonstrated that activins, particularly activin A but also activin B, are also negative regulators of muscle, and therefore a follistatin polypeptide that inhibits both the myostatin/GDF11 ligand group and the activin A/activin B ligand group may provide a more potent muscle effect. Given that FST_{FD2} confers activin A and B binding, the disclosure provides polypeptides comprising FST_{FD1}-FST_{FD2} (SEQ ID NO: 12) and FST_{FD1}-FST_{FD2}-FST_{FD3} (SEQ ID NO: 13), as well as constructs comprising FST_{ND}-FST_{FD1}-FST_{FD2} (SEQ ID NO: 14) and, for example, one or more heterologous polypeptides.

1 CENVDCGPGK KCRMNKKKPK RCVCAPDCSN ITWKGVCGL DGKTYRNECA
 10 51 LLKARCKEQP ELEVQYQGRC CRDVFCPGSS TCVVDQTNNA YCVTCNRICP
 101 EPASSEQYLC GNDGVTYSSA CHLRKATCLL GRSIGLAYEG KC
 (SEQ ID NO: 12)

1 CENVDCGPGK KCRMNKKKPK RCVCAPDCSN ITWKGVCGL DGKTYRNECA
 51 LLKARCKEQP ELEVQYQGRC CRDVFCPGSS TCVVDQTNNA YCVTCNRICP
 15 101 EPASSEQYLC GNDGVTYSSA CHLRKATCLL GRSIGLAYEG KCCEDIQCTG
 151 GKKCLWDFKV GRGRCSLCDE LCPDSKSDEP VCASDNATYA SECAMKEAAC
 201 SSGVLLEVKH SGSC (SEQ ID NO: 13)

1 CWLRQAKNGR CQVLYKTELS KEECCSTGRL STSWTEEDVN DNTLFKWMIF
 51 NGGAPNCIPC KETCENVDCG PGKKCRMNKK NKPRCVCAPD CSNITWKGVP
 20 101 CGLDGKTYRN ECALLKARCK EQPELEVQYQ GRCCRDVFCP GSSTCVVDQT
 151 NNAYCVTCNR ICPEPASSEQ YLCGNDGVTY SSACHLRKAT CLLGRSIGLA
 201 YEGKC (SEQ ID NO: 14)

A follistatin polypeptide of 291 amino acids (representing a truncation of the naturally occurring FST315) may have advantageous properties in certain embodiments. Accordingly, unprocessed (SEQ ID NO: 15) and mature FST291 (SEQ ID NO: 16) polypeptides are included in the disclosure and may be combined with heterologous proteins. Moreover, it will be appreciated that any of the initial amino acids G or N, prior to the first cysteine may be removed by processing or intentionally eliminated without any consequence, and polypeptides comprising such slightly shorter polypeptides are further included, such as the example shown below (SEQ ID NO: 17).

1 MVRARHQPGG LLLLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL
 51 SKEECCSTGR LSTSWTEEDV NDNTLFKWMI FNGGAPNCIP CKETCENVDC
 101 GPGKKCRMNK KNKPRCVCAP DCSNITWKGVP VCGLDGKTYR NECALLKARC
 151 KEQPELEVQY QGRCKKTCRD VFCPGSSTCV VDQTNNAICV TCNRICPEPA

201 SSEQYLCGND GVTYSSACHL RKATCLLGRS IGLAYEGKCI KAKSCEDIQC
 251 TGGKKCLWDF KVGRGRCSLC DELCPDSKSD EPVCASDNAT YASECAMKEA
 301 ACSSGVLLEV KHSGSCNSIS (SEQ ID NO: 15)

1 GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLFKWM
 5 51 IFNGGAPNCI PCKETCENVD CGPGKKCRMN KKNKPRCVCA PDCSNITWKG
 101 PVCGLDGKTY RNECALLKAR CKEQPELEVQ YQGRCKKTCR DVFCPGSSTC
 151 VVDQTNNAVC VTCNRICPEP ASSEQYLCGN DGVTYSSACH LRKATCLLGR
 201 SIGLAYEGKC IKAKSCEDIQ CTGGKKCLWD FKVGRGRCSL CDELCPDSKS
 251 DEPVCASDNA TYASECAMKE AACSSGVLLE VKHSGSCNSI S
 10 (SEQ ID NO: 16)

1 CWLRQAKNGR CQVLYKTELS KEECCSTGRL STSWTEEDVN DNTLFKWMIF
 51 NGGAPNCIPC KETCENVDCG PGKKCRMNKK NKPRVCAPD CSNITWKGPV
 101 CGLDGKTYRN ECALLKARCK EQPELEVQYQ GRCKKTCRDV FCPGSSTCVV
 151 DQTNNAVCVT CNRICPEPAS SEQYLCGNDG VTYSSACHLR KATCLLGRSI
 15 201 GLAYEGKCIK AKSCEDIQCT GGKKCLWDFK VGRGRCSLCD ELCPSKSD
 251 PVCASDNATY ASECAMKEAA CSSGVLLEVK HSGSCNSIS
 (SEQ ID NO: 17)

Follistatin proteins herein may be referred to as FST. If followed by a number, such as FST288, this indicates that the protein is the 288-amino-acid isoform of follistatin. If presented as FST288-Fc, this indicates that an Fc domain is fused to the C-terminus of FST288, which may or may not include an intervening linker. The Fc in this instance may be any immunoglobulin Fc portion as that term is defined herein. If presented as FST288-G1Fc, this indicates that the Fc portion of human IgG1 is fused at the C-terminal of FST288. Unless indicated to the contrary, a protein described with this nomenclature will represent a human follistatin protein.

Closely related to the native follistatin isoforms encoded by *FSTN* is a naturally occurring protein encoded by the *FSTL3* gene and known alternatively as follistatin-related gene (FLRG), follistatin-like 3 (FSTL3), or follistatin-related protein (FSRP) [Schneyer et al (2001) Mol Cell Endocrinol 180:33-38]. Like follistatin, FLRG binds to myostatin, activins, and GDF11 with high affinity and thereby inhibits their bioactivity in vivo [Sidis et al (2006) Endocrinology 147:3586-3597]. Unlike follistatin, FLRG does not possess a heparin-binding sequence, cannot bind to cell-surface proteoglycans, and therefore is a less potent inhibitor of activin than is FST288 in the immediate vicinity of the cell surface. In contrast to follistatin, FLRG also circulates in the blood bound to mature myostatin, and thus resembles myostatin

propeptide in this regard [Hill et al (2002) J Biol Chem 277:40735-40741. Unlike follistatin, FLRG deficiency in mice is not lethal, although it does cause a variety of metabolic phenotypes [Mukherjee et al (2007) Proc Natl Acad Sci USA 104:1348-1353].

The overall structure of FLRG closely resembles that of follistatin. Native human
5 FLRG precursor is a single-chain polypeptide which comprises four domains: a signal sequence (amino acids 1-26 of SEQ ID NO: 18), an N-terminal domain (FLRG_{ND}) (amino acids 38-96 of SEQ ID NO: 18), and two follistatin domains referred to herein as FLRG_{FD1} (amino acids 99-167 of SEQ ID NO: 18) and FLRG_{FD2} (amino acids 171-243 of SEQ ID NO: 18).

10 The term "FLRG polypeptide" is used to refer to polypeptides comprising any naturally occurring polypeptide of FLRG as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity. In certain preferred embodiments, FLRG polypeptides of the disclosure bind to and/or inhibit activity of myostatin, GDF11, or activin, particularly activin A (*e.g.*, ligand-mediated activation of
15 ActRIIA and/or ActRIIB Smad2/3 signaling). Variants of FLRG polypeptides that retain ligand binding properties can be identified using routine methods to assay interactions between FLRG and ligands (see, *e.g.*, US 6,537,966). In addition, methods for making and testing libraries of polypeptides are described herein and such methods also pertain to making and testing variants of FLRG.

20 For example, FLRG polypeptides include polypeptides comprising an amino acid sequence derived from the sequence of any known FLRG having a sequence at least about 80% identical to the sequence of a FLRG polypeptide (for example, SEQ ID NOs: 18-25), and optionally at least 85%, 90%, 95%, 97%, 99% or greater identity to any of SEQ ID NOs: 18-25. The term "FLRG fusion polypeptide" may refer to fusion proteins that comprise any
25 of the polypeptides mentioned above along with a heterologous (non-FLRG) portion. An amino acid sequence is understood to be heterologous to FLRG if it is not uniquely found in human FLRG, represented by SEQ ID NO: 18. Many examples of heterologous portions are provided herein, and such heterologous portions may be immediately adjacent, by amino acid sequence, to the FLRG polypeptide portion of a fusion protein, or separated by intervening
30 amino acid sequence, such as a linker or other sequence.

The human FLRG precursor has the following amino acid sequence (SEQ ID NO: 18) (amino acids 1-263 of NCBI Reference Sequence NP_005851.1), with the signal peptide

indicated by dotted underline, the N-terminal domain (FLRG_{ND}) indicated by dashed underline, and the two follistatin domains (FST_{FD1}, FST_{FD2}) indicated by solid underline.

```

1  MRPGAPGPLW PLPWGALAWA VGFVSSMSGG NPAPGGVCWL QQGQEQATCSL
51  VLQTDVTRAE CCASGNIDTA WSNLTHPGNK INLLGFLGLV HCLPCKDSCD
5  101  GVECGPGKAC RMLGGRPRCE CAPDCSGLPA RLQVCGSDGA TYRDECELRA
151  ARCRGHPDLS VMYRGRCRKS CEHVVCPRPQ SCVVDQTGSA HCVVCRAAPC
201  PVPSSPGQEL CGNNNVTYIS SCHMRQATCF LGRSIGVRHA GSCAGTPEEP
251  PGGESAEIEEE NFV (SEQ ID NO: 18)

```

Mature (processed) human FLRG comprises the following amino acid sequence (SEQ ID NO: 19) (amino acids 38-263 of NCBI Reference Sequence NP_005851.1) with the N-terminal domain indicated by dashed underline and the two follistatin domains indicated by solid underline. Moreover, it will be appreciated that any of the amino acids (positions 27-37 of SEQ ID NO: 18) prior to the first cysteine (position 38 in SEQ ID NO: 18) may be included without substantial consequence, and polypeptides comprising such slightly longer polypeptides are included.

```

1  CWLQQGQEQEAT CSLVLQTDVT RAECCASGNI DTAWSNLTHP GNKINLLGFL
51  GLVHCLPCKD SCDGVECGPG KACRMLGGRP RCECAPDCSG LPARLQVCGS
101  DGATYRDECE LRAARCRGHP DLSVMYRGRC RKSCEHVVCPRPQSCVVDQT
151  GSAHCVVCRA APCPVPSSPG QELCGNNNVYI YISSCHMRQA TCFLGRSIGV
20  201  RHAGSCAGTP EEPPGGESAE EEENFV
      (SEQ ID NO: 19)

```

In certain aspects, the disclosure includes polypeptides comprising the FLRG_{ND} domain (SEQ ID NO: 20), which interacts differently with myostatin compared with activin A [Cash et al (2012) J Biol Chem 287:1043-1053], as set forth below, and, for example, one or more heterologous polypeptides. Moreover, it will be appreciated that any of the initial amino acids G or N prior to the first cysteine may be deleted, as in the example shown below (SEQ ID NO: 21).

```

1  GVCWLQQGQEQE ATCSLVLQTD VTRAECCASG NIDTAWSNLT HPGNKINLLG
51  FLGLVHCLPC (SEQ ID NO: 20)
30  1  CWLQQGQEQEAT CSLVLQTDVT RAECCASGNI DTAWSNLTHP GNKINLLGFL
51  GLVHCLPC (SEQ ID NO: 21)

```

In certain aspects, the disclosure includes polypeptides comprising the FLRG_{FD1} domain as set forth below (SEQ ID NO: 22), and, for example, one or more heterologous polypeptides.

1 CDGVECGPGK ACRMLGGRPR CECAPDCSGL PARLQVCGSD GATYRDECEL
 5 51 RAARCRGHPD LSVMYRGRC (SEQ ID NO: 22)

In certain aspects, the disclosure includes polypeptides comprising the FST_{FD2} domain as set forth below (SEQ ID NO: 23), and, for example, one or more heterologous polypeptides.

1 CEHVVCPRPQ SCVVDQTGSA HCVVCRAAPC PVPSSPGQEL CGNNNVTYIS
 10 51 SCHMRQATCF LGRSIGVRHA GSC (SEQ ID NO: 23)

A FLRG_{FD} sequence may be advantageously maintained in structural context by expression as a polypeptide further comprising the FLRG_{ND} domain. Accordingly, the disclosure includes polypeptides comprising the FLRG_{ND}-FLRG_{FD1} sequence (SEQ ID NO: 24) and the FLRG_{ND}-FLRG_{FD1}-FLRG_{FD2} sequence (SEQ ID NO: 25), as set forth below, and, for example, one or more heterologous polypeptides. Moreover, it will be appreciated that any of the initial amino acids G or N, prior to the first cysteine may be removed by processing or intentionally eliminated without any consequence, and polypeptides comprising such slightly shorter polypeptides are further included.

1 GVCWLQQGQE ATCSLVLQTD VTRAECASG NIDTAWSNLT HPGNKINLLG
 20 51 FLGLVHCLPC KCDGVECGPG KACRMLGGRP RCECAPDCSG LPARLQVCGS
 101 DGATYRDECE LRAARCRGHP DLSVMYRGRC (SEQ ID NO: 24)

1 GVCWLQQGQE ATCSLVLQTD VTRAECASG NIDTAWSNLT HPGNKINLLG
 51 FLGLVHCLPC KCDGVECGPG KACRMLGGRP RCECAPDCSG LPARLQVCGS
 101 DGATYRDECE LRAARCRGHP DLSVMYRGRC CEHVVCPRPQ SCVVDQTGSA
 25 151 HCVVCRAAPC PVPSSPGQEL CGNNNVTYIS SCHMRQATCF LGRSIGVRHA
 201 GSC (SEQ ID NO: 25)

If presented as FLRG-Fc, this indicates that an Fc domain is fused to the C-terminus of FLRG, which may or may not include an intervening linker. The Fc in this instance may be any immunoglobulin Fc portion as that term is defined herein. If presented as FLRG-G1Fc, this indicates that the Fc portion of IgG1 is fused at the C-terminus of FLRG. Unless indicated to the contrary, a protein described with this nomenclature will represent a human FLRG protein.

In addition to *FSTN* and *FSTL3*, two other genes have been identified whose protein products contain a follistatin domain motif and function as extracellular inhibitors of myostatin and GDF11. In humans, these closely related genes are named WFIKKN1 and WFIKKN2 based on their shared domain structure which includes a whey acidic protein domain, a follistatin-Kazal domain, an immunoglobulin domain, two tandem domains related to Kunitz-type protease inhibitor modules, and a netrin domain [Trexler et al (2001) Proc Natl Acad Sci USA 98:3705-3709; Trexler et al (2002) Biol Chem 383:223-228]. WFIKKN2 is also known as WFIKKN-related protein (WFIKKNRP), and murine counterparts of these proteins are named GDF-associated serum protein-2 (Gasp2) and Gasp1, respectively, based on their ligand-binding ability [Hill et al (2003) Mol Endocrinol 17:1144-1154].

Native WFIKKN1 (GASP2) and WFIKKN2 (GASP1) proteins possess overlapping activity profiles that are nonetheless distinct from each other and from follistatin or FLRG. WFIKKNs bind with high affinity to myostatin, GDF11, and in some cases to myostatin propeptide, with binding to mature ligand mediated primarily by the follistatin domain (WFIKKN1_{FD}, WFIKKN2_{FD}) and propeptide binding mediated primarily by the netrin domain [Hill et al (2003) Mol Endocrinol 17:1144-1154; Kondas et al (2008) J Biol Chem 283:23677-23684]. In contrast to follistatin and FLRG, neither WFIKKN1 nor WFIKKN2 bind activin [Szláma et al (2010) FEBS J 277:5040-5050]. WFIKKN proteins inhibit myostatin and GDF11 signaling by blocking their access to activin type II receptors [Lee et al (2013) Proc Natl Acad Sci USA 110:E3713-E3722]. Due to the presence of several protease inhibitory modules in both WFIKKNs, it is likely that they also regulate the action of multiple types of proteases. The tissue expression patterns of WFIKKN1 differ prenatally and postnatally from that of WFIKKN2, thus supporting the view that the two proteins serve distinct roles [Trexler et al (2002) Biol Chem 383:223-228].

Additional lines of evidence implicate WFIKKNs in the regulation of skeletal muscle mass. Mice with homozygous deletion of *WFIKKN1* or *WFIKKN2* display phenotypes consistent with overactivity of myostatin and GDF11, including a reduction in muscle weight, a shift in fiber type from fast glycolytic type IIb fibers to fast oxidative type IIa fibers, and impaired muscle regeneration (Lee et al (2013) Proc Natl Acad Sci USA 110:E3713-E3722). Conversely, broad overexpression of *WFIKKN2* in mice leads mainly to a hypermuscular phenotype [Monestier et al (2012) BMC Genomics 13:541-551]. Although both WFIKKN proteins bind to myostatin, WFIKKN1 and WFIKKN2 may interact differently with myostatin propeptide and thus may differentially block the activation of ActRIIA or ActRIIB

by semilalent myostatin, which is the native complex between myostatin and a single myostatin propeptide chain [Szláma et al (2013) FEBS J 280:3822-3839]. Taken together, follistatin-related fusion proteins comprising a WFIKKN1 or WFIKKN2 polypeptide as disclosed herein would be predicted to increase skeletal muscle mass in vivo without causing potentially undesirable effects associated with inhibition of endogenous activins.

The term "WFIKKN1 polypeptide" is used to refer to polypeptides comprising any naturally occurring polypeptide of WFIKKN1 as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity. In certain preferred embodiments, WFIKKN1 polypeptides of the disclosure bind to and/or inhibit activity of myostatin, myostatin propeptide, complexes between myostatin and its propeptide, GDF11, and potentially activins (*e.g.*, ligand-mediated activation of ActRIIA and/or ActRIIB Smad2/3 signaling). Variants of WFIKKN1 polypeptides that retain ligand binding properties can be identified using routine methods to assay interactions between WFIKKN1 and ligands [see, *e.g.*, Kondas et al (2008) J Biol Chem 283:23677-23684; Szláma et al (2013) FEBS J 280:3822-3839]. In addition, methods for making and testing libraries of polypeptides are described herein and such methods also pertain to making and testing variants of WFIKKN1.

For example, WFIKKN1 polypeptides include polypeptides comprising an amino acid sequence derived from the sequence of any known WFIKKN1 polypeptide having a sequence at least about 80% identical to the sequence of a WFIKKN1 polypeptide (for example, SEQ ID NOs: 26-28), and optionally at least 85%, 90%, 95%, 97%, 99% or greater identity to any of SEQ ID NOs: 26-28. The term "WFIKKN1 fusion polypeptide" may refer to fusion proteins that comprise any of the polypeptides mentioned above along with a heterologous (non-WFIKKN1) portion. An amino acid sequence is understood to be heterologous to WFIKKN1 if it is not uniquely found in human WFIKKN1, represented by SEQ ID NO: 26. Many examples of heterologous portions are provided herein, and such heterologous portions may be immediately adjacent, by amino acid sequence, to the WFIKKN1 polypeptide portion of a fusion protein, or separated by intervening amino acid sequence, such as a linker or other sequence.

The human WFIKKN1 precursor has the following amino acid sequence (SEQ ID NO: 26) (NCBI Ref Seq NP_444514.1), with the signal peptide indicated by dotted underline and the follistatin domain (WFIKKN1_{FD}) indicated by solid underline.

1 MPALRPLLPL LLLLRLTSGA GLLPGLGSHP GVCNQLSPN LWVDAQSTCE
 51 RECSRQDCA AA EKCCINVC GLHSCVAARF PGSPAAPTTA ASCEGFVCPQ
 101 QGSDCDIWDG QPVCRCRDR EKEPSFTCAS DGLTYYNRCY MDAEACLRGL
 151 HLHIVPCKHV LSWPPSSPGP PETTARPTPG AAPVPPALYS SPSPQAVQVG
 5 201 GTASLHCDVS GRPPPAVTWE KQSHQRENLI MRPDQMYGNV VVTSIGQLVL
 251 YNARPEDAGL YTCTARNAAG LLRADFP LSV VQREPARDA PSIPAPAECL
 301 PDVQACTGPT SPHLVLWHYD PQRGGCMTFP ARGCDGAARG FETYEACQQA
 351 CARGPGDACV LPAVQGPCRG WEPRWAYSPL LQQCHPFVYG GCEGNGNMFH
 401 SRESCEDACP VPRTPPCRAC RLRSKLALS CRSDFAIVGR LTEVLEEPEA
 10 451 AGGIARVALE DVLKDDKMGL KFLGTKYLEV TLSGMDWACP CPNMTAGDGP
 501 LVIMGEVRDG VAVLDAGSYV RAASEKRVK ILELLEKQAC ELLNRFQD
 (SEQ ID NO: 26)

Mature (processed) human WFIKKN1 has the following amino acid sequence (SEQ ID NO: 27) with the follistatin domain indicated by solid underline. Moreover, it will be appreciated that any of the 13 amino acids prior to the first cysteine may be removed by processing or intentionally eliminated without substantial consequence, and polypeptides comprising such slightly smaller polypeptides are further included.

1 AGLLPGLGSH PGVCNQLSP NLWVDAQSTC ERECSRQDC AA EKCCINVC
 51 CGLHSCVAAR FPGSPAAPT T AASCEGFVCP QGSDCDIWD QPVCRCRDR
 20 101 CEKEPSFTCA SDGLTYYNRC YMDAEACLRG LHLHIVPCKH VLSWPPSSPG
 151 PPETTARPTP GAAPVPPALY SSPSPQAVQV GGTASLHCDV SGRPPPAVTW
 201 EKQSHQRENL IMRPDQMYGN VVTSIGQLV LYNARPEDAG LYTCTARNA
 251 GLLRADFP LSV VVQREPARDA APSIPAPAECL LPDVQACTGP TSPHLVLWHY
 301 DPQRGGCMTF PARGCDGAAR GFETYEACQQ ACARGPGDAC VLPVQGPCR
 25 351 GWEPRWAYSPL LLQQCHPFVY GGCEGNGNMF HSRESCEDAC VPRTPPCRAC
 401 CRLRSKLALS LCRSDFAIVG RLTEVLEEPE AAGGIARVAL EDVLKDDKMG
 451 LKFLGTKYLE VTLSGMDWAC PCPNMTAGDG PLVIMGEVRD GAVLDAGSY
 501 VRAASEKRVK KILELLEKQA CELLNRFQD (SEQ ID NO: 27)

In certain aspects, the disclosure includes polypeptides comprising the WFIKKN1_{FD} domain as set forth below (SEQ ID NO: 28), and, for example, one or more heterologous polypeptides.

1 CEGFVCPQQG SDCDIWDGQP VRCRCRDRCEK EPSFTCASDG LTYYNRCYMD
 51 AEACLRGLHL HIVPC (SEQ ID NO: 28)

If presented as WFIKKN1-Fc, this indicates that an Fc portion is fused to the C-terminus of WFIKKN1, which may or may not include an intervening linker. The Fc in this

instance may be any immunoglobulin Fc portion as that term is defined herein. If presented as WFIKKN1-G1Fc, this indicates that the Fc portion of IgG1 is fused at the C-terminus of WFIKKN1. Unless indicated to the contrary, a protein described with this nomenclature will represent a human WFIKKN1 protein.

5 The term "WFIKKN2 polypeptide" includes polypeptides comprising any naturally occurring polypeptide of WFIKKN2 as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity. In certain preferred embodiments, WFIKKN2 polypeptides of the disclosure bind to and/or inhibit activity of myostatin, myostatin propeptide, complexes between myostatin and its propeptide, 10 GDF11, and potentially activins (*e.g.*, ligand-mediated activation of ActRIIA and/or ActRIIB Smad2/3 signaling). Variants of WFIKKN2 polypeptides that retain ligand binding properties can be identified using routine methods to assay interactions between WFIKKN2 and ligands [see, *e.g.*, Kondas et al (2008) J Biol Chem 283:23677-23684; Szláma et al (2013) FEBS J 280:3822-3839]. In addition, methods for making and testing libraries of polypeptides are 15 described herein and such methods also pertain to making and testing variants of WFIKKN2.

For example, WFIKKN2 polypeptides include polypeptides comprising an amino acid sequence derived from the sequence of any known WFIKKN2 polypeptide having a sequence at least about 80% identical to the sequence of a WFIKKN2 polypeptide (for example, SEQ ID NOs: 29-33), and optionally at least 85%, 90%, 95%, 97%, 99% or greater identity to any 20 of SEQ ID NOs: 29-33. The term "WFIKKN2 fusion polypeptide" may refer to fusion proteins that comprise any of the polypeptides mentioned above along with a heterologous (non-WFIKKN2) portion. An amino acid sequence is understood to be heterologous to WFIKKN2 if it is not uniquely found in human WFIKKN2, represented by SEQ ID NO: 29. Many examples of heterologous portions are provided herein, and such heterologous portions 25 may be immediately adjacent, by amino acid sequence, to the WFIKKN2 polypeptide portion of a fusion protein, or separated by intervening amino acid sequence, such as a linker or other sequence.

The human WFIKKN2 precursor has the following amino acid sequence (SEQ ID NO: 29) (NCBI Ref Seq NP_783165.1), with the signal peptide indicated by dotted underline and the follistatin domain (WFIKKN2_{FD}) indicated by solid underline. 30

```

1  MWAPRCRRFW SRWEQVAALL LLLLLLGVPP RSLALPPIRY SHAGICPNDM
51  NPNLWVDAQS TCRRECETDQ ECETYEKCCP NVCGTKSCVA ARYMDVKGKK
101  GPVGMPEAT CDHFMCLQQG SECDIWDGQP VCKCKDRCEK EPSFTCASDG

```

151 LTYYNRCYMD AEACSKGITL AVVTCRYHFT WPNTSPPPPE TTMHPTTASP
 201 ETPELDMAAP ALLNNPVHQ S VTMGETVSFL CDVVGRPRPE ITWEKQLEDR
 251 ENVVMRPNHV RGNVVVTNIA QLVIYNAQLQ DAGIYTCTAR NVAGVLRADF
 301 PLSVVRGHQA AATSESSPNG TAFPAAECLK PPDSEDCGEE QTRWHFDAQA
 5 351 NNCLTFTFGH CHRNLNHFET YEACMLACMS GPLAACSLPA LQGPKAYAP
 401 RWAYNSQTGQ CQSFVYGGCE GNGNNFESRE ACEESCPFPR GNQRCRACKP
 451 RQKLVT SFCR SDFVILGRVS ELTEEPDSGR ALVTVDEV LK DEKMGLKFLG
 501 QEPLEVTLLH VDWACPCPNV TVSEMPLIIM GEVDGGMAML RPDSFVGASS
 551 ARRVRKLREV MHKKTCDVLK EFLGLH (SEQ ID NO: 29)

10 Mature (processed) human WFIKKN2 has the following amino acid sequence (SEQ ID NO: 30) with the follistatin domain indicated by single underline. Moreover, it will be appreciated that any of the 11 amino acids prior to the first cysteine may be removed by processing or intentionally eliminated without substantial consequence, and polypeptides comprising such slightly smaller polypeptides are further included.

15 1 LPPIRYSHAG ICPNDMNP NL WVDAQSTCRR ECETDQECET YEKCCPNVCG
 51 TKSCVAARYM DVKGGKGPVG MPKEATCDHF MCLQQGSECD IWDGQPVCKC
 101 KDRCEKEPSF TCASDGLTY NRCYMDAEAC SKGITLAVVT CRYHFTWPNT
 151 SPPPPETTMH PTTASPETPE LDMAAPALLN NPVHQSVTMG ETVSFLCDVV
 201 GRPRPEITWE KQLEDRENVV MRPNHVRGNV VVTNIAQLVI YNAQLQDAGI
 20 251 YTCTARNVAG VLRADFPLSV VRGHQAAATS ESSPNGTAFP AADECLKPPDS
 301 EDCGEEQTRW HFDAQANNCL TFTFGHCHRN LNHFETYEAC MLACMSGPLA
 351 ACSLPALQGP CKAYAPRWAY NSQTGQCQSF VYGGCEGNGN NFESREACEE
 401 SCFPFRGNQR CRACKPRQKL VTSFCRSDFV ILGRVSELTE EPDSGRALVT
 451 VDEV LKDEKM GLKFLGQEPL EVTLLHVDWA CPCPNVTVSE MPLIIMGEVD
 25 501 GGMAMLRPDS FVGASSARRV RKLREVMHKK TCDVLKEFLG LH
 (SEQ ID NO: 30)

In certain aspects, the disclosure includes polypeptides comprising the WFIKKN2_{FD} domain as set forth below (SEQ ID NO: 31), and, for example, one or more heterologous polypeptides.

30 1 CDHFMCLQQG SECDIWDGQP VCKCKDRCEK EPSFTCASDG LTYYNRCYMD
 51 AEACSKGITL AVVTC (SEQ ID NO: 31)

The murine WFIKKN2 (GASP1) precursor has the following amino acid sequence (SEQ ID NO: 32) (NCBI Ref Seq NP_861540.2), with the signal peptide indicated by dotted underline and the follistatin domain (WFIKKN2_{FD}) indicated by solid underline.

1 MCAPGYHRFW FHWGLLLLLL LEAPLRGLAL PPIRYSHAGI CPNDMNPNLW
 51 VDAQSTCKRE CETDQECETY EKCCPNVCGT KSCVAARYMD VKGKKGVPVM
 101 PKEATCDHFM CLQQGSECDI WDGQPVCKCK DRCEKEPSFT CASDGLTYYN
 151 RCFMDAEACS KGITLSVVTC RYHFTWPNTS PPPPETTVHP TTASPETLGL
 5 201 DMAAPALLNH PVHQSVTVGE TVSFLCDVVG RPRPELTWEK QLEDRENVVM
 251 RPNHVRGNV VTNIAQLVIY NVQPQDAGIY TCTARNVAGV LRADFPLSVV
 301 RGGQARATSE SSLNGTAFPA TECLKPPDSE DCGEEQTRWH FDAQANNCLT
 351 FTFGHCHHNL NHFETYEACM LACMSGPLAI CSLPALQGPC KAYVPRWAYN
 401 SQTGLCQSFV YGGCEGNGNN FESREACEES CPFPRGNQHC RACKPRQKL
 10 451 TSFCRSDFVI LGRVSELTEE QDSGRALVTV DEVLKDEKMG LKFLGREPLE
 501 VLLHVDWTC PCPNVTVGET PLIIMGEVDG GMAMLRPDSF VGASSTRVR
 551 KLREVMYKKT CDVLKDFLGL Q (SEQ ID NO: 32)

Mature (processed) murine WFIKKN2 has the following amino acid sequence (SEQ ID NO: 33) with the follistatin domain indicated by single underline. Moreover, it will be appreciated that any of the 11 amino acids prior to the first cysteine may be removed by processing or intentionally eliminated without substantial consequence, and polypeptides comprising such slightly smaller polypeptides are further included.

1 LPPIRYSHAG ICPNDMNPNL WVDAQSTCKR ECETDQECET YEKCCPNVCG
 51 TKSCVAARYM DVKGGKKGVPV MPKEATCDHF MCLQQGSECD IWDGQPVCKC
 20 101 KDRCEKEPSF TCASDGLTYY NRCFMDAEAC SKGITLSVVT CRYHFTWPNT
 151 SPPPPETTVH PTTASPETLG LDMAAPALLN HPVHQSVTVG ETVSFLCDVVG
 201 GRPRPELTWE KQLEDRENVV MRPNHVRGNV VVTNIAQLVI YNVQPQDAGI
 251 YTCTARNVAG VLRADFPLSV VRGGQARATS ESSLNGTAFP ATECLKPPDS
 301 EDCGEEQTRW HFDAQANNCL TFTFGHCHHN LNHFETYEAC MLACMSGPLA
 25 351 ICSLPALQGP CKAYVPRWAY NSQTGLCQSF VYGGCEGNGN NFESREACEE
 401 SCPFPRGNQH CRACKPRQKL VTSFCRSDFV ILGRVSELTE EQDSGRALVT
 451 VDEVLKDEKM GLKFLGREPL EVTLLHVDWT CPCPNVTVGE TPLIIMGEVD
 501 GGMAMLRPDS FVGASSTRRV RKLREVMYKK TCDVLKDFLG LQ
 (SEQ ID NO: 33)

If presented as WFIKKN2-Fc, this indicates that an Fc portion is fused to the C-terminus of WFIKKN2, which may or may not include an intervening linker. The Fc in this instance may be any immunoglobulin Fc portion as that term is defined herein. If presented as WFIKKN2-G1Fc, this indicates that the Fc portion of IgG1 is fused at the C-terminus of WFIKKN2. Unless indicated to the contrary, a protein described with this nomenclature will represent a human WFIKKN2 protein.

In certain aspects, the disclosure provides follistatin-related polypeptides and follistatin-related fusion proteins that may inhibit the ligands myostatin, activin A, activin B, and/or GDF11. The term “follistatin-related polypeptide” is used herein to refer to a single polypeptide chain comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99 or 100% identical to the amino acid sequence of at least one follistatin domain (for example, FST_{FD1}, FST_{FD2}, FST_{FD3}, FLRG_{FD1}, FLRG_{FD2}, WFIKKN1_{FD}, or WFIKKN2_{FD}). The term “follistatin-related polypeptide” refers to polypeptides comprising any naturally occurring polypeptide product of the follistatin gene, FLRG (FSTL3, FSRP) gene, WFIKKN1 (GASP2) gene, or WFIKKN2 (GASP1) gene as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity, including, for example, ligand binding (e.g., myostatin, GDF11, activin A, activin B). For example, follistatin-related polypeptides include polypeptides comprising an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 97%, 99% or greater identity to SEQ ID NOs: 1-33.

The term “follistatin-related fusion polypeptide” refers to single-chain fusion proteins that comprise a follistatin-related polypeptide mentioned above along with a heterologous portion in a single amino acid sequence. An amino acid sequence is understood to be heterologous to follistatin, FLRG, WFIKKN1, or WFIKKN2 if it is not uniquely found in human FST315, (represented by SEQ ID NO: 3), human FLRG (represented by SEQ ID NO: 18), human WFIKKN1 (represented by SEQ ID NO: 25), or human WFIKKN2 (represented by SEQ ID NO: 28). Many examples of heterologous portions are provided herein, and such heterologous portions may be immediately adjacent, by amino acid sequence, to the follistatin-related polypeptide portion of a fusion protein, or separated by intervening amino acid sequence, such as a linker or other sequence, and may be positioned amino-terminal to or carboxy-terminal to a portion that is a follistatin-related polypeptide.

In certain embodiments, the follistatin-related fusion proteins described herein refer to an asymmetric heterodimeric fusion protein comprising a polypeptide chain derived from a naturally occurring follistatin-related polypeptide. Accordingly, in certain embodiments, the methods of the present disclosure are directed to the use of one or more follistatin-related fusion proteins, including fusion proteins comprising a single-arm follistatin-related polypeptide containing at least one follistatin domain, optionally in combination with one or more supportive therapies, to treat a variety of applicable disorders, particularly disorders that may be addressed by inhibition of the ligands to which such follistatin-related fusion protein

binds. For example, a follistatin-related fusion protein that binds to and inhibits myostatin, and optionally other ligands such as GDF11, activin A and/or activin B may be used to increase skeletal muscle mass in a subject in need thereof and/or treat or prevent skeletal muscle loss or a skeletal muscle disorder in a subject in need thereof.

5 As shown herein, follistatin-related polypeptides may be more amenable to expression as active proteins when expressed in a monomeric form, but such proteins tend to be challenging to purify and also tend to have a short serum residence time (half-life), which are both undesirable in the therapeutic setting. The purification problem may be solved by incorporation of an interaction pair with intrinsic characteristics that facilitate purification,
10 such as properties associated with a constant domain portion (e.g., Fc portion) of an IgG that enable purification of attached proteins by methods already known in the art. A common mechanism for improving serum half-life is to express a polypeptide as a homodimeric fusion protein with a constant domain portion of an IgG. However, follistatin-related polypeptides expressed as homodimeric proteins (e.g. in an Fc fusion construct) may not be as active or
15 well-produced as the monomeric form. As demonstrated herein, the problem may be solved by fusing the monomeric form to a half-life extending moiety, and surprisingly, this can be expeditiously achieved by expressing such proteins as an asymmetric heterodimeric fusion protein in which one member of a binding pair is fused to a follistatin-related polypeptide and another member of the binding pair is fused to no other moiety or a heterologous moiety,
20 resulting in a highly active follistatin-related polypeptide coupled with an improvement in serum half-life conferred by the binding pair.

The numbering of amino acids in the follistatin-related polypeptides is based on the sequence of SEQ ID NOs: 1, 3, 15, 18, 26, 29, or 32, regardless of whether the native leader sequence is used.

25 The terms used in this specification generally have their ordinary meanings in the art, within the context of this disclosure and in the specific context where each term is used. Certain terms are discussed below or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions and methods of the disclosure and how to make and use them. The scope or meaning of any use of a term will be apparent from
30 the specific context in which the term is used.

“Homologous,” in all its grammatical forms and spelling variations, refers to the relationship between two proteins that possess a “common evolutionary origin,” including

proteins from superfamilies in the same species of organism, as well as homologous proteins from different species of organism. Such proteins (and their encoding nucleic acids) have sequence homology, as reflected by their sequence similarity, whether in terms of percent identity or by the presence of specific residues or motifs and conserved positions.

5 The term “sequence similarity,” in all its grammatical forms, refers to the degree of identity or correspondence between nucleic acid or amino acid sequences that may or may not share a common evolutionary origin.

 However, in common usage and in the instant application, the term “homologous,” when modified with an adverb such as “highly,” may refer to sequence similarity and may or
10 may not relate to a common evolutionary origin.

 "Percent (%) sequence identity" with respect to a reference polypeptide (or nucleotide) sequence is defined as the percentage of amino acid residues (or nucleic acids) in a candidate sequence that are identical to the amino acid residues (or nucleic acids) in the reference polypeptide (nucleotide) sequence, after aligning the sequences and introducing gaps, if
15 necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can
20 determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid (nucleic acid) sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has
25 been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison
30 parameters are set by the ALIGN-2 program and do not vary.

As used herein “does not substantially bind to X” is intended to mean that an agent has a K_D that is greater than about 10^{-7} , 10^{-6} , 10^{-5} , 10^{-4} or greater (e.g., no detectable binding by the assay used to determine the K_D) for “X”.

5 2. Follistatin-Related Fusion Polypeptides

In certain aspects, the disclosure concerns follistatin-related fusion polypeptides comprising one or more follistatin domains (e.g., FST-Fc polypeptides, FLRG-Fc polypeptides, WFIKKN1-Fc polypeptides, and WFIKKN2-Fc polypeptides). In certain embodiments, the polypeptides disclosed herein may form protein complexes comprising a first polypeptide covalently or non-covalently associated with a second polypeptide, wherein the first polypeptide comprises the amino acid sequence of a follistatin-related polypeptide and the amino acid sequence of a first member of an interaction pair; and the second polypeptide comprises the amino acid sequence of a second member of the interaction pair, and wherein the second polypeptide does not comprise a follistatin-related polypeptide. The interaction pair may be any two polypeptide sequences that interact to form a complex, particularly a heterodimeric complex although operative embodiments may also employ an interaction pair that forms a homodimeric sequence. As described herein, one member of the interaction pair may be fused to a follistatin-related polypeptide, such as a polypeptide comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to the sequence of any of SEQ ID NOs: 1-33. Preferably, the interaction pair is selected to confer an improved means of protein purification or an improved serum half-life, or to act as an adapter on to which another moiety, such as a polyethylene glycol moiety, is attached to provide an improved serum half-life relative to the monomeric form of the follistatin-related polypeptide.

As described above, follistatin is characterized by four cysteine-rich regions (i.e., FST_{ND}, FST_{FD1}, FST_{FD2}, and FST_{FD3}) that are thought to mediate follistatin ligand binding. Similarly, FLRG is characterized by three cysteine-rich regions (i.e., FLRG_{ND}, FLRG_{FD1}, and FLRG_{FD2}) and WFIKKN1 or WFIKKN2 are each characterized by a cysteine-rich region (WFIKKN1_{FD} or WFIKKN2_{FD}) that are thought to mediate binding to myostatin, activins, or GDF11. Furthermore, researchers have demonstrated that polypeptide constructs comprising only one of the three follistatin domains in FST (e.g., FST_{FD1}) retains strong affinity towards certain follistatin ligands (e.g., myostatin) and are biologically active *in vivo*. See Nakatani *et*

al. (2008) FASEB J 22:477-487. Therefore, variant follistatin-related polypeptides of the disclosure may comprise one or more active portions of a follistatin protein. For example, constructs of the disclosure may begin at a residue corresponding to amino acids 30-95 of SEQ ID NO: 1 and end at a position corresponding to amino acids 316-344 of SEQ ID NO: 1.

5 Other examples include constructs that begin at a position from 30-95 of SEQ ID NO: 1 and end at a position corresponding to amino acids 164-167 or 238-244.

The follistatin, FLRG, WFIKKN1, and WFIKKN2 polypeptide variants described herein may be combined in various ways with each other or with heterologous amino acid sequences. For example, variant follistatin-related fusion proteins of the disclosure include

10 polypeptides that comprise one or more follistatin domains selected from FST_{FD1} (amino acids 95-164 of SEQ ID NO: 1; i.e., SEQ ID NO: 7), FST_{FD2} (amino acids 168-239 of SEQ ID NO:1; i.e., SEQ ID NO: 8), or FST_{FD3} (amino acids 245-316 of SEQ ID NO:1; SEQ ID NO: 9) as well as proteins that comprise one or more follistatin domains selected from a sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to FST_{FD1}

15 (SEQ ID NO: 7), FST_{FD2} (SEQ ID NO: 8), or FST_{FD3} (SEQ ID NO: 9). Similarly, variant follistatin-related fusion proteins of the disclosure include polypeptides that comprise one or more follistatin domains selected from FLRG_{FD1} (amino acids 99-167 of SEQ ID NO: 18; i.e., SEQ ID NO: 22), FLRG_{FD2} (amino acids 171-243 of SEQ ID NO: 18; i.e., SEQ ID NO: 23), WFIKKN1_{FD} (amino acids 93-157 of SEQ ID NO: 26; i.e., SEQ ID NO: 28), or WFIKKN2_{FD}

20 (amino acids 111-175 of SEQ ID NO: 29; i.e., SEQ ID NO: 31) as well as proteins that comprise one or more follistatin domains selected from a sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to FST_{FD1} (SEQ ID NO: 7), FST_{FD2} (SEQ ID NO: 8), FST_{FD3} (SEQ ID NO: 9), FLRG_{FD1} (SEQ ID NO: 22), FLRG_{FD2} (SEQ ID NO: 23), WFIKKN1_{FD} (SEQ ID NO: 28), or WFIKKN2_{FD} (SEQ ID NO: 31).

25 These follistatin domains may be combined in any order within a variant follistatin-related polypeptide of the disclosure provided that such recombinant proteins maintain the desired activity including, for example, follistatin ligand-binding activity (e.g., myostatin) and biological activity (e.g., inducing muscle mass and/or muscle strength). Examples of such variant follistatin polypeptides include, for example, polypeptides having domain

30 structures such as FST_{FD1}-FST_{FD2}-FST_{FD3}, FST_{FD1}-FST_{FD3}, FST_{FD1}-FST_{FD1}-FST_{FD3}, FST_{FD1}-FST_{FD2}, FST_{FD1}-FST_{FD1}, FST_{ND}-FST_{FD1}-FST_{FD2}-FST_{FD3}, FST_{ND}-FST_{FD1}-FST_{FD2}, FST_{ND}-FST_{FD1}-FST_{FD1}, FST_{ND}-FST_{FD1}-FST_{FD3}, FST_{ND}-FST_{FD1}-FST_{FD1}-FST_{FD3}, and polypeptides obtained by fusing other heterologous polypeptides to the N-termini or the C-termini of these

polypeptides. Examples of variant follistatin-related polypeptides include, for example, polypeptides having domain structures such as FLRG_{FD1}-FLRG_{FD1}, FLRG_{FD1}-FLRG_{FD2}, FLRG_{FD1}-FLRG_{FD1}-FLRG_{FD2}, FLRG_{ND}-FLRG_{FD1}-FLRG_{FD1}, FLRG_{ND}-FST_{FD1}-FST_{FD2}, and polypeptides obtained by fusing other heterologous polypeptides to the N-termini or the C-termini of these polypeptides. These domains may be directly fused or linked via a linker polypeptide. Optionally, polypeptide linkers may be any sequence and may comprise 1-100, 1-50, preferably 1-10, and more preferably 1-5 amino acids. In certain aspects, preferred linkers contain no cysteine amino acids or protease cleavage sites.

In some embodiments, follistatin variants of the disclosure have reduced or abolished binding affinity for one or more follistatin ligands. In certain aspects, the disclosure provides follistatin variants that have reduced or abolished binding affinity for activin. In certain aspects, the disclosure provides follistatin variants that have reduced or abolished binding affinity for activin but retain high affinity for myostatin. In certain aspects, the disclosure provides follistatin variants that have reduced or abolished binding affinity for GDF11 but retain high affinity for myostatin.

In certain embodiments, the present invention relates to antagonizing a ligand of follistatin or another follistatin-related polypeptide, such as an activin, GDF8 or GDF11, with a subject follistatin-related fusion polypeptide. Thus, compositions and methods of the present disclosure are useful for treating disorders associated with abnormal or undesirably high activity of one or more such ligands.

The follistatin related polypeptides of the disclosure may comprise a signal sequence. The signal sequence can be a native signal sequence of a follistatin precursor (e.g., amino acids 1-29 of SEQ ID NO:1), FLRG precursor (e.g., amino acids 1-26 of SEQ ID NO: 18), WFIKKN1 precursor (e.g., amino acids 1-19 of SEQ ID NO: 26), WFIKKN2 precursor (e.g., amino acids 1-34 of SEQ ID NO: 29), or a signal sequence from another protein, such as tissue plasminogen activator (TPA) signal sequence or a honey bee melatin (HBM) signal sequence.

Further N-linked glycosylation sites (N-X-S/T) may be added to a follistatin related polypeptide, and may increase the serum half-life of a follistatin-related fusion protein. N-X-S/T sequences may be generally introduced at positions outside the ligand-binding pocket. N-X-S/T sequences may be introduced into the linker between the follistatin sequence and the Fc or other fusion component. Such a site may be introduced with minimal effort by

introducing an N in the correct position with respect to a pre-existing S or T, or by introducing an S or T at a position corresponding to a pre-existing N. Any S that is predicted to be glycosylated may be altered to a T without creating an immunogenic site, because of the protection afforded by the glycosylation. Likewise, any T that is predicted to be glycosylated
5 may be altered to an S. Accordingly, a follistatin-related polypeptide variant may include one or more additional, non-endogenous N-linked glycosylation consensus sequences.

In certain embodiments, the present disclosure contemplates making functional variants by modifying the structure of a follistatin-related polypeptide for such purposes as enhancing therapeutic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to
10 proteolytic degradation *in vivo*). Modified follistatin-related polypeptides can also be produced, for instance, by amino acid substitution, deletion, or addition. For instance, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (e.g., conservative mutations) will not have a
15 major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Whether a change in the amino acid sequence of a follistatin-related polypeptide results in a functional homolog can be readily determined by assessing the ability of the variant
20 follistatin-related polypeptide to produce a response in cells in a fashion similar to the wild-type follistatin-related polypeptide, or to bind to one or more ligands, such as myostatin or activin in a manner similar to wild-type follistatin-related polypeptide.

In certain embodiments, the present invention contemplates specific mutations of the follistatin-related polypeptides so as to alter the glycosylation of the polypeptide. Such mutations may be selected so as to introduce or eliminate one or more glycosylation sites,
25 such as O-linked or N-linked glycosylation sites. Asparagine-linked glycosylation recognition sites generally comprise a tripeptide sequence, asparagine-X-threonine (where "X" is any amino acid) which is specifically recognized by appropriate cellular glycosylation enzymes. The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the wild-type follistatin-related polypeptide
30 (for O-linked glycosylation sites). A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence. Another means of increasing the number of carbohydrate moieties on a

follistatin-related polypeptide is by chemical or enzymatic coupling of glycosides to the follistatin-related polypeptide. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine; (b) free carboxyl groups; (c) free sulfhydryl groups such as those of cysteine; (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline; (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan; or (f) the amide group of glutamine. These methods are described in WO 87/05330 published Sep. 11, 1987, and in Aplin and Wriston (1981) *CRC Crit. Rev. Biochem.*, pp. 259-306, incorporated by reference herein. Removal of one or more carbohydrate moieties may be accomplished chemically and/or enzymatically. Chemical deglycosylation may involve, for example, exposure of the follistatin-related polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the amino acid sequence intact. Chemical deglycosylation is further described by Hakimuddin et al. (1987) *Arch. Biochem. Biophys.* 259:52 and by Edge et al. (1981) *Anal. Biochem.* 118:131. Enzymatic cleavage of carbohydrate moieties on follistatin-related polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al. (1987) *Meth. Enzymol.* 138:350. The sequence of a follistatin-related polypeptide may be adjusted, as appropriate, depending on the type of expression system used, as mammalian, yeast, insect and plant cells may all introduce differing glycosylation patterns that can be affected by the amino acid sequence of the peptide. In general, follistatin-related fusion proteins for use in humans will be expressed in a mammalian cell line that provides proper glycosylation, such as HEK293, COS, or CHO cell lines, although other mammalian expression cell lines are expected to be useful as well.

This disclosure further contemplates a method of generating variants, particularly sets of combinatorial variants of a follistatin-related polypeptide, including, optionally, truncation variants; pools of combinatorial mutants are especially useful for identifying functional variant sequences. The purpose of screening such combinatorial libraries may be to generate, for example, follistatin-related polypeptide variants that have altered properties, such as altered pharmacokinetics, or altered ligand binding. A variety of screening assays are provided below, and such assays may be used to evaluate variants. For example, a follistatin-related polypeptide variant may be screened for ability to bind to a ligand such as activin A,

B, C or E, GDF8 or GDF11, or to prevent binding of a ligand to a ligand receptor such as ActRIIA or ActRIIB.

The activity of a follistatin-related polypeptide or its variants may also be tested in a cell-based or *in vivo* assay. For example, the effect of a follistatin-related polypeptide variant on the expression of genes involved in muscle production may be assessed. This may, as
5 needed, be performed in the presence of one or more recombinant ligand proteins (e.g., myostatin or activin A), and cells may be transfected so as to produce a follistatin-related polypeptide and/or variants thereof, and optionally, a ligand. Likewise, a follistatin-related polypeptide may be administered to a mouse or other animal, and one or more muscle
10 properties, such as muscle mass or strength may be assessed. Such assays are well known and routine in the art. A responsive reporter gene may be used in such cell lines to monitor effects on downstream signaling.

Combinatorially-derived variants can be generated which have a selective potency relative to a naturally occurring follistatin-related polypeptide. Such variant proteins, when
15 expressed from recombinant DNA constructs, can be used in gene therapy protocols. Likewise, mutagenesis can give rise to variants which have intracellular half-lives dramatically different than the corresponding a wild-type follistatin-related polypeptide. For example, the altered protein can be rendered either more stable or less stable to proteolytic degradation or other processes which result in destruction of, or otherwise inactivation of a
20 native follistatin-related polypeptide. Such variants, and the genes which encode them, can be utilized to alter follistatin-related polypeptide levels by modulating the half-life of the follistatin-related polypeptides.

In certain embodiments, the follistatin-related polypeptides of the disclosure may further comprise post-translational modifications in addition to any that are naturally present
25 in the follistatin-related polypeptides. Such modifications include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. As a result, the follistatin-related polypeptides may contain non-amino acid elements, such as polyethylene glycols, lipids, poly- or mono-saccharide, and phosphates. Effects of such non-amino acid elements on the functionality of a follistatin-related polypeptide may be tested as
30 described herein for other follistatin-related polypeptide variants. When a follistatin-related polypeptide is produced in cells by cleaving a nascent form of the follistatin-related polypeptide, post-translational processing may also be important for correct folding and/or function of the protein. Different cells (such as CHO, COS, HeLa, MDCK, 293, WI38, NIH-

3T3 or HEK293) have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the follistatin-related polypeptides.

In certain aspects, functional variants or modified forms of the follistatin-related polypeptides include fusion proteins having at least a portion of a follistatin-related polypeptide and one or more fusion domains. Well known examples of such fusion domains include, but are not limited to, polyhistidine, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, an immunoglobulin heavy chain constant region (e.g., an Fc), maltose binding protein (MBP), or human serum albumin. A fusion domain may be selected so as to confer a desired property. For example, some fusion domains are particularly useful for isolation of the fusion proteins by affinity chromatography. For the purpose of affinity purification, relevant matrices for affinity chromatography, such as glutathione-, amylase-, and nickel- or cobalt- conjugated resins are used. Many of such matrices are available in “kit” form, such as the Pharmacia GST purification system and the QIAexpress™ system (Qiagen) useful with (HIS₆) fusion partners. As another example, a fusion domain may be selected so as to facilitate detection of the follistatin-related polypeptides. Examples of such detection domains include the various fluorescent proteins (e.g., GFP) as well as “epitope tags,” which are usually short peptide sequences for which a specific antibody is available. Well-known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus haemagglutinin (HA), and c-myc tags. In some cases, the fusion domains have a protease cleavage site, such as for Factor Xa or thrombin, which allows the relevant protease to partially digest the fusion proteins and thereby liberate the recombinant proteins therefrom. The liberated proteins can then be isolated from the fusion domain by subsequent chromatographic separation. In certain preferred embodiments, a follistatin-related polypeptide is fused with a domain that stabilizes the follistatin-related polypeptide *in vivo* (a “stabilizer” domain). By “stabilizing” is meant anything that increases serum half-life, regardless of whether this is because of reduced degradation, reduced clearance by the kidney, or another pharmacokinetic effect. Fusions with the Fc portion of an immunoglobulin are known to confer desirable pharmacokinetic properties on a wide range of proteins. Likewise, fusions to human serum albumin can confer desirable properties. Other types of fusion domains that may be selected include multimerizing (e.g., dimerizing, tetramerizing) domains and functional domains (that confer an additional biological function, such as further stimulation of muscle growth).

As specific examples, the present disclosure provides fusion proteins comprising follistatin-related polypeptides fused to a polypeptide comprising a constant domain of an immunoglobulin, such as a CH1, CH2 or CH3 domain of an immunoglobulin or an Fc. Fc domains derived from human IgG1, IgG2, IgG3, and IgG4 are provided below. Other mutations are known that decrease either CDC or ADCC activity, and collectively, any of these variants are included in the disclosure and may be used as advantageous components of a follistatin fusion protein. Optionally, the IgG1 Fc domain of SEQ ID NO: 34 has one or more mutations at residues such as Asp-265, Lys-322, and Asn-434 (numbered in accordance with the corresponding full-length IgG1). In certain cases, the mutant Fc domain having one or more of these mutations (e.g., Asp-265 mutation) has reduced ability of binding to the Fcγ receptor relative to a wildtype Fc domain. In other cases, the mutant Fc domain having one or more of these mutations (e.g., Asn-434 mutation) has increased ability of binding to the MHC class I-related Fc-receptor (FcRN) relative to a wildtype Fc domain.

An example of a native amino acid sequence that may be used for the Fc portion of human IgG1 (G1Fc) is shown below (SEQ ID NO: 34). Dotted underline indicates the hinge region, and solid underline indicates positions with naturally occurring variants. In part, the disclosure provides polypeptides comprising amino acid sequences with 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 34. Naturally occurring variants in G1Fc would include D134 and L136 according to the numbering system used in SEQ ID NO: 34 (see Uniprot P01857).

```

1  THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
51  VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
101 VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSREEMTKNQ VSLTCLVKGF
151 YPSDIAVEWE SNGQPENNYK TTPPVLDSG SFFLYSKLTV DKSRWQQGNV
25  201 FSCSVMEAL HNHYTQKSL S LSPGK (SEQ ID NO: 34)

```

An example of a native amino acid sequence that may be used for the Fc portion of human IgG2 (G2Fc) is shown below (SEQ ID NO: 35). Dotted underline indicates the hinge region, solid underline indicates positions with naturally occurring variants, and double underline indicates positions where there are data base conflicts in the sequence (according to UniProt P01859). In part, the disclosure provides polypeptides comprising amino acid sequences with 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 35.

```

1  VECPPCPAPP VAGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVQ
51  FNWYVDGVEV HNAKTKPREE QFNSTFRVVS VLTVVHQDWL NGKEYKCKVS

```

101 NKGLPAPIEK TISKTKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP
 151 SDIAVEWESN GQPENNYKTT PPMLDSDGSF FLYSKLTVDK SRWQQGNVFS
 201 CSVMHEALHN HYTQKSLSLSPGK (SEQ ID NO: 35)

Two examples of amino acid sequences that may be used for the Fc portion of human
 5 IgG3 (G3Fc) are shown below. The hinge region in G3Fc can be up to four times as long as in
 other Fc chains and contains three identical 15-residue segments preceded by a similar 17-residue
 segment. The first G3Fc sequence shown below (SEQ ID NO: 36) contains a short hinge region
 consisting of a single 15-residue segment, whereas the second G3Fc sequence (SEQ ID NO: 37)
 contains a full-length hinge region. In each case, dotted underline indicates the hinge region, and
 10 solid underline indicates positions with naturally occurring variants according to UniProt
 P01859. In part, the disclosure provides polypeptides comprising amino acid sequences with
 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NOs: 36, 37.

1 EPKSCDTPPP CPRCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD
 51 VSHEDPEVQF KWYVDGVEVEH NAKTKPREEQ YNSTFRVVS V LTVLHQDWLN
 15 101 GKEYKCKVSN KALPAPIEKT ISKTKGQPRE PQVYTLPPSR EEMTKNQVSL
 151 TCLVKGFYPS DIAVEWESSG QPENNYNTTP PMLDSDGSFF LYSKLTVDKS
 201 RWQQGNIFSC SVMHEALHNR FTQKSLSLSP GK (SEQ ID NO: 36)

1 ELKTPLGDDT HTCPRCPEPK SCDTPPPCPR CPEPKSCDTP PPCPRCPEPK
 20 51 SCDTPPPCPR CPAPELLGGP SVFLFPPKPK DTLMISRTPV VTCVVVDVSH
 101 EDPEVQFKWY VDGVEVEHNAK TKPREEQYNS TFRVVSVLTV LHQDWLNGKE
 151 YKCKVSNKAL PAPIEKTISK TKGQPREPQV YTLPPSREEM TKNQVSLTCL
 201 VKGFYPSDIA VEWESSGQPE NNYNTTPPML DSDGSFFLYS KLTVDKSRWQ
 251 QGNIFSCSVM HEALHNRFTQ KSLSLSPGK (SEQ ID NO: 37)

25 Naturally occurring variants in G3Fc (for example, see Uniprot P01859) include
 E68Q, V69, P76L, E79Q, Y81F, D97N, N100D, T124A, S169N, S169del, F221Y when
 converted to the numbering system used in SEQ ID NO: 36, and the present disclosure
 provides fusion proteins comprising G3Fc domains containing one or more of these
 variations. In addition, the human immunoglobulin IgG3 gene (*IGHG3*) shows a structural
 30 polymorphism characterized by different hinge lengths [see Uniprot P01859]. Specifically,
 variant WIS is lacking most of the V region and all of the CH1 region. It has an extra
 interchain disulfide bond at position 7 in addition to the 11 normally present in the hinge
 region. Variant ZUC lacks most of the V region, all of the CH1 region, and part of the hinge.
 Variant OMM may represent an allelic form or another gamma chain subclass. The present

disclosure provides additional fusion proteins comprising G3Fc domains containing one or more of these variants.

An example of a native amino acid sequence that may be used for the Fc portion of human IgG4 (G4Fc) is shown below (SEQ ID NO: 38). Dotted underline indicates the hinge region. In part, the disclosure provides polypeptides comprising amino acid sequences with 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 38.

```

1  ESKYGPPCPS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ
51 EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE
101 YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL
10 151 VKGFYPSDIA VEWESNGQPE NNYKTTTPVL DSDGSFFLYS RLTVDKSRWQ
201 EGNVFSCSVM HEALHNHYTQ KSLSLSLGK (SEQ ID NO: 38)

```

A variety of engineered mutations in the Fc domain are presented herein with respect to the G1Fc sequence (SEQ ID NO: 34), and analogous mutations in G2Fc, G3Fc, and G4Fc can be derived from their alignment with G1Fc in Figure 1. Due to unequal hinge lengths, analogous Fc positions based on isotype alignment (Figure 1) possess different amino acid numbers in SEQ ID NOs: 34, 35, 36, and 38.

A problem that arises in large-scale production of asymmetric immunoglobulin-based proteins from a single cell line is known as the “chain association issue”. As confronted prominently in the production of bispecific antibodies, the chain association issue concerns the challenge of efficiently producing a desired multichain protein from among the multiple combinations that inherently result when different heavy chains and/or light chains are produced in a single cell line [see, for example, Klein et al (2012) mAbs 4:653-663]. This problem is most acute when two different heavy chains and two different light chains are produced in the same cell, in which case there are a total of 16 possible chain combinations (although some of these are identical) when only one is typically desired. Nevertheless, the same principle accounts for diminished yield of a desired multichain fusion protein that incorporates only two different (asymmetric) heavy chains.

Various methods are known in the art that increase desired pairing of Fc-containing fusion polypeptide chains in a single cell line to produce a preferred asymmetric fusion protein at acceptable yields [see, for example, Klein et al (2012) mAbs 4:653-663]. Methods to obtain desired pairing of Fc-containing chains include, but are not limited to, charge-based pairing (electrostatic steering), “knobs-into-holes” steric pairing, and SEEDbody pairing. See,

for example, Ridgway et al (1996) Protein Eng 9:617-621; Merchant et al (1998) Nat Biotech 16:677-681; Davis et al (2010) Protein Eng Des Sel 23:195-202. As demonstrated herein, an asymmetric Fc fusion protein comprising a single WFIKKN2 polypeptide arm, in which charge-based pairing promotes the correct matching of asymmetric polypeptide chains, inhibits myostatin activity in a cell-based reporter gene assay with substantially greater potency (lower IC₅₀) than a symmetric Fc fusion protein comprising dual WFIKKN2 polypeptide arms.

In certain embodiments, the disclosure provides desired pairing of asymmetric Fc-containing polypeptide chains using Fc sequences engineered to be complementary on the basis of charge pairing (electrostatic steering). One of a pair of Fc sequences with electrostatic complementarity can be arbitrarily fused to the follistatin-related polypeptide (e.g., follistatin polypeptide, FLRG polypeptide, WFIKKN1 polypeptide, or WFIKKN2 polypeptide) of the construct, with or without an optional linker, to generate a follistatin-related fusion polypeptide. This single chain can be coexpressed in a cell of choice along with the Fc sequence complementary to the first Fc to favor generation of the desired multichain construct (a follistatin-related fusion protein). In this example based on electrostatic steering, SEQ ID NO: 39 [human G1Fc(E134K/D177K)] and SEQ ID NO: 40 [human G1Fc(K170D/K187D)] are examples of complementary Fc sequences in which the engineered amino acid substitutions are double underlined, and the follistatin-related polypeptide of the construct can be fused to either SEQ ID NO: 39 or SEQ ID NO: 40, but not both. Given the high degree of amino acid sequence identity between native hG1Fc, native hG2Fc, native hG3Fc, and native hG4Fc, it can be appreciated that amino acid substitutions at corresponding positions in hG2Fc, hG3Fc, or hG4Fc (see Figure 1) will generate complementary Fc pairs which may be used instead of the complementary hG1Fc pair below (SEQ ID NOs: 39, 40).

```

1   THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
51  VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
101 VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSRKEMTKNQ VSLTCLVKGF
151 YPSDIAVEWE SNGQPENNYK TTPPVLKSDG SFFLYSKLTV DKSRWQQGNV
30  201 FSCSVMEAL HNHYTQKSL S LSPGK          (SEQ ID NO: 39)

```

```

1   THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
51  VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
101 VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSREEMTKNQ VSLTCLVKGF
151 YPSDIAVEWE SNGQPENNYD TTPPVLDSDG SFFLYSDLTV DKSRWQQGNV

```

201 FSCSVMHEAL HNHYTQKSLS LSPGK (SEQ ID NO: 40)

In part, the disclosure provides desired pairing of asymmetric Fc-containing polypeptide chains using Fc sequences engineered for steric complementarity. In part, the disclosure provides knobs-into-holes pairing as an example of steric complementarity. One of a pair of Fc sequences with steric complementarity can be arbitrarily fused to the follistatin-related polypeptide (e.g., follistatin polypeptide, FLRG polypeptide, WFIKKN1 polypeptide, or WFIKKN2 polypeptide) of the construct, with or without an optional linker, to generate a follistatin-related fusion polypeptide. This single chain can be coexpressed in a cell of choice along with the Fc sequence complementary to the first Fc to favor generation of the desired multichain construct. In this example based on knobs-into-holes pairing, SEQ ID NO: 41 [human G1Fc(T144Y)] and SEQ ID NO: 42 [human G1Fc(Y185T)] are examples of complementary Fc sequences in which the engineered amino acid substitutions are double underlined, and the follistatin-related polypeptide of the construct can be fused to either SEQ ID NO: 41 or SEQ ID NO: 42, but not both. Given the high degree of amino acid sequence identity between native hG1Fc, native hG2Fc, native hG3Fc, and native hG4Fc, it can be appreciated that amino acid substitutions at corresponding positions in hG2Fc, hG3Fc, or hG4Fc (see Figure 1) will generate complementary Fc pairs which may be used instead of the complementary hG1Fc pair below (SEQ ID NOs: 41, 42).

1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 20 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVYTL P SREEMTKNQ VSLYCLVKGF
 151 YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV
 201 FSCSVMHEAL HNHYTQKSLS LSPGK (SEQ ID NO: 41)

1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 25 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVYTL P SREEMTKNQ VSLTCLVKGF
 151 YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLTSKLTV DKSRWQQGNV
 201 FSCSVMHEAL HNHYTQKSLS LSPGK (SEQ ID NO: 42)

An example of Fc complementarity based on knobs-into-holes pairing combined with an engineered disulfide bond is disclosed in SEQ ID NO: 43 [hG1Fc(S132C/T144W)] and SEQ ID NO: 44 [hG1Fc(Y127C/T144S/L146A/Y185V)]. The engineered amino acid substitutions in these sequences are double underlined, and the follistatin-related polypeptide of the construct can be fused to either SEQ ID NO: 43 or SEQ ID NO: 44, but not both. Given the high degree of

amino acid sequence identity between native hG1Fc, native hG2Fc, native hG3Fc, and native hG4Fc, it can be appreciated that amino acid substitutions at corresponding positions in hG2Fc, hG3Fc, or hG4Fc (see Figure 1) will generate complementary Fc pairs which may be used instead of the complementary hG1Fc pair below (SEQ ID NOs: 43, 44).

5 1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVYTLP PCREEMTKNQ VSLWCLVKGF
 151 YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFFLYSKLTV DKSRWQQGNV
 201 FSCSVMEAL HNHYTQKSLS LSPGK (SEQ ID NO: 43)

10 1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVVTLP PSREEMTKNQ VSLSCAVKGF
 151 YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFFLVSKLTV DKSRWQQGNV
 201 FSCSVMEAL HNHYTQKSLS LSPGK (SEQ ID NO: 44)

15 In part, the disclosure provides desired pairing of asymmetric Fc-containing polypeptide chains using Fc sequences engineered to generate interdigitating β -strand segments of human IgG and IgA C_H3 domains. Such methods include the use of strand-exchange engineered domain (SEED) C_H3 heterodimers allowing the formation of SEEDbody fusion proteins [see, for example, Davis et al (2010) Protein Eng Design Sel 23:195-202]. One of a pair of Fc sequences
 20 with SEEDbody complementarity can be arbitrarily fused to the follistatin-related polypeptide (e.g., follistatin polypeptide, FLRG polypeptide, WFIKKN1 polypeptide, or WFIKKN2 polypeptide) of the construct, with or without an optional linker, to generate a follistatin-related fusion polypeptide. This single chain can be coexpressed in a cell of choice along with the Fc sequence complementary to the first Fc to favor generation of the desired multichain construct.
 25 In this example based on SEEDbody (Sb) pairing, SEQ ID NO: 45 [hG1Fc(Sb_{AG})] and SEQ ID NO: 46 [hG1Fc(Sb_{GA})] are examples of complementary IgG Fc sequences in which the engineered amino acid substitutions from IgA Fc are double underlined, and the follistatin-related polypeptide of the construct can be fused to either SEQ ID NO: 45 or SEQ ID NO: 46, but not both. Given the high degree of amino acid sequence identity between native hG1Fc,
 30 native hG2Fc, native hG3Fc, and native hG4Fc, it can be appreciated that amino acid substitutions at corresponding positions in hG1Fc, hG2Fc, hG3Fc, or hG4Fc (see Figure 1) will generate an Fc monomer which may be used in the complementary IgG-IgA pair below (SEQ ID NOs: 45, 46).

1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PFRPEVHLLP PSREEMTKNQ VSLTCLARGF
 151 YPKDIAVEWE SNGQPENNYK TTPSRQEPSQ GTTTFAVTSK LTVDKSRWQQ
 5 201 GNVFSCSVMH EALHNHYTQK TISLSPGK (SEQ ID NO: 45)

 1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVYTLF PPSEELALNE LVTLTCLVKG
 151 FYPSDIAVEW ESNGQELPRE KYLTWAPVLD SDGSFFLYSI LRVAAEDWKK
 10 201 GDTFSCSVMH EALHNHYTQK SLDRSPGK (SEQ ID NO: 46)

It is understood that different elements of the fusion proteins may be arranged in any manner that is consistent with the desired functionality. For example, a follistatin-related polypeptide may be placed C-terminal to a heterologous domain, or, alternatively, a heterologous domain may be placed C-terminal to a follistatin-related polypeptide. The follistatin-related polypeptide domain and the heterologous domain need not be adjacent in a fusion protein, and additional domains or amino acid sequences may be included C- or N-terminal to either domain or between the domains.

As used herein, the term "immunoglobulin Fc domain" or simply "Fc" is understood to mean the carboxyl-terminal portion of an immunoglobulin chain constant region, preferably an immunoglobulin heavy chain constant region, or a portion thereof. For example, an immunoglobulin Fc region may comprise 1) a CH1 domain, a CH2 domain, and a CH3 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, or 5) a combination of two or more domains and an immunoglobulin hinge region. In a preferred embodiment the immunoglobulin Fc region comprises at least an immunoglobulin hinge region a CH2 domain and a CH3 domain, and preferably lacks the CH1 domain. It is also understood that a follistatin polypeptide may comprise only a domain of an immunoglobulin, such as a CH1 domain, a CH2 domain or a CH3 domain. Many of these domains confer desirable pharmacokinetic properties as well as dimerization or higher order multimerization.

In one embodiment, the class of immunoglobulin from which the heavy chain constant region is derived is IgG (I γ) (γ subclasses 1, 2, 3, or 4). Other classes of immunoglobulin, IgA (I α), IgD (I δ), IgE (I ϵ) and IgM (I μ), may be used. The choice of appropriate immunoglobulin heavy chain constant region is discussed in detail in U.S. Pat.

Nos. 5,541,087 and 5,726,044. The choice of particular immunoglobulin heavy chain constant region sequences from certain immunoglobulin classes and subclasses to achieve a particular result is considered to be within the level of skill in the art. The portion of the DNA construct encoding the immunoglobulin Fc region preferably comprises at least a
5 portion of a hinge domain, and preferably at least a portion of a CH₃ domain of Fc gamma or the homologous domains in any of IgA, IgD, IgE, or IgM.

Furthermore, it is contemplated that substitution or deletion of amino acids within the immunoglobulin heavy chain constant regions may be useful in the practice of the methods and compositions disclosed herein. One example would be to introduce amino acid
10 substitutions in the upper CH₂ region to create an Fc variant with reduced affinity for Fc receptors (Cole *et al.* (1997) *J. Immunol.* 159:3613). Additionally, in many instances, the C-terminal lysine, or K, will be removed and thus any of the polypeptides described herein may omit the C-terminal K that is found in an Fc domain, such as those shown in SEQ ID NOs: 34-46.

15 In certain embodiments, the follistatin-related polypeptides of the present disclosure contain one or more modifications that are capable of stabilizing the follistatin-related polypeptides. For example, such modifications enhance the *in vitro* half-life of the follistatin-related polypeptides, enhance circulatory half-life of the follistatin-related polypeptides or
20 reducing proteolytic degradation of the follistatin-related polypeptides. Such stabilizing modifications include, but are not limited to, fusion proteins (including, for example, fusion proteins comprising a follistatin-related polypeptide and a stabilizer domain), modifications of a glycosylation site (including, for example, addition of a glycosylation site to a follistatin-related polypeptide), and modifications of carbohydrate moiety (including, for example, removal of carbohydrate moieties from a follistatin-related polypeptide). In the case of
25 fusion proteins, a follistatin-related polypeptide is fused to a stabilizer domain such as an IgG molecule (e.g., an Fc domain). As used herein, the term “stabilizer domain” not only refers to a fusion domain (e.g., Fc) as in the case of fusion proteins, but also includes nonproteinaceous modifications such as a carbohydrate moiety, or nonproteinaceous polymer, such as polyethylene glycol.

30 In certain embodiments, the present invention makes available isolated and/or purified forms of the follistatin-related polypeptides, which are isolated from, or otherwise substantially free of, other proteins. In certain embodiments, the present invention facilitates purification of therapeutically active follistatin-related polypeptides by attachment of an

interaction pair (for example, an Fc domain) possessing properties advantageous for purification.

In certain embodiments, follistatin-related polypeptides (unmodified or modified) of the disclosure can be produced by a variety of art-known techniques. For example, such
5 follistatin-related polypeptides can be synthesized using standard protein chemistry techniques such as those described in Bodansky, M. Principles of Peptide Synthesis, Springer Verlag, Berlin (1993) and Grant G. A. (ed.), Synthetic Peptides: A User's Guide, W. H. Freeman and Company, New York (1992). In addition, automated peptide synthesizers are commercially available (e.g., Advanced ChemTech Model 396; Milligen/Biosearch 9600).
10 Alternatively, the follistatin-related polypeptides, fragments or variants thereof may be recombinantly produced using various expression systems (e.g., E. coli, Chinese Hamster Ovary cells, COS cells, baculovirus) as is well known in the art (also see below). In a further embodiment, the modified or unmodified follistatin-related polypeptides may be produced by digestion of naturally occurring or recombinantly produced full-length follistatin-related
15 polypeptides by using, for example, a protease, e.g., trypsin, thermolysin, chymotrypsin, pepsin, or paired basic amino acid converting enzyme (PACE). Computer analysis (using a commercially available software, e.g., MacVector, Omega, PCGene, Molecular Simulation, Inc.) can be used to identify proteolytic cleavage sites. Alternatively, such follistatin-related polypeptides may be produced from naturally occurring or recombinantly produced full-
20 length follistatin-related polypeptides such as standard techniques known in the art, such as by chemical cleavage (e.g., cyanogen bromide, hydroxylamine).

Any of the follistatin-related polypeptides disclosed herein may be combined with one or more additional follistatin-related polypeptides of the disclosure to achieve a desired effect such as treating a follistatin-related disorder (e.g., increase muscle mass and/or strength in a
25 subject in need thereof, treat or prevent muscle loss in a subject in need thereof, treat or prevent one or more complications of muscle loss in a subject in need thereof; increase hemoglobin concentration or red blood cell count in a subject in need thereof, treat or prevent inadequate hemoglobin concentration or red blood cell count in a subject in need thereof, treat or prevent one or more complications of inadequate hemoglobin concentration or red
30 blood cell count in a subject in need thereof; increase bone mass and/or strength in a subject in need thereof, treat or prevent bone loss or fragility in a subject in need thereof, treat or prevent one or more complications of bone loss or fragility in a subject in need thereof; or treat cancer in a subject in need thereof). For example, a follistatin polypeptide disclosed

herein can be used in combination with i) one or more additional FLRG polypeptides disclosed herein, ii) one or more WFIKKN1 polypeptides disclosed herein, and/or iii) one or more WFIKKN2 polypeptides disclosed herein.

5 3. Nucleic Acids Encoding Follistatin-Related Polypeptides

In certain aspects, the invention provides isolated and/or recombinant nucleic acids encoding any of the follistatin-related polypeptides disclosed herein. The subject nucleic acids may be single stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. These nucleic acids are may be used, for example, in methods for making
10 follistatin-related polypeptides.

For example, the following sequence encodes a naturally occurring human follistatin precursor polypeptide (SEQ ID NO: 47) (nucleotides 359-1390 of NCBI Reference Sequence: NM_013409.2):

```

Atggtccgcgagggcaccagccgggtgggctttgcctcctgctgctgctg
15 ctctgccagttcatggaggaccgcagtgccaggctgggaactgctggctc
cgtaagcgaagaacggccgctgccaggtcctgtacaagaccgaactgagc
aaggaggagtgctgcagcaccggccggctgagcacctcgtggaccgaggag
gacgtgaatgacaacacactcttcaagtggatgatthttcaacgggggccc
cccaactgcatcccctgtaaagaaacgtgtgagaacgtggactgtggacct
20 gggaaaaaatgccgaatgaacaagaagaacaaaccccgctgcgtctgcgcc
ccggattgttccaacatcacctggaaggggtccagtctgcgggctggatggg
aaaacctaccgcaatgaatgtgcactcctaaggcaagatgtaaagagcag
ccagaactggaagtccagtaccaaggcagatgtaaaaagacttgctcgggat
gttttctgtccaggcagctccacatgtgtggtggaccagaccaataatgcc
25 tactgtgtgacctgtaatcggatttgcccagagcctgcttcctctgagcaa
tatctctgtgggaatgatggagtcacctactccagtgcctgccacctgaga
aaggctacctgctgctgggcagatctattggattagcctatgagggaaag
tgtatcaaagcaaagtcctgtgaagatatccagtgcactggtgggaaaaaa
tgtttatgggatttcaagggtgggagaggccgggtgtccctctgtgatgag
30 ctgtgccctgacagtaagtccgatgagcctgtctgtgccagtgacaatgcc
acttatgccagcgagtgtgcatgaaggaagctgcctgctcctcaggtgtg
ctactggaagtaaagcactccggatcttgcaactccatthtcggaagacacc

```

gaggaagaggaggaagatgaagaccaggactacagctttcctatatcttct
attctagagtgg (SEQ ID NO: 47)

The following sequence encodes the mature FST315 polypeptide (SEQ ID NO: 48).

Gggaactgctggctccgtcaagcgaagaacggccgctgccaggctcctgtaca
5 agaccgaactgagcaaggaggagtgctgcagcaccggccggctgagcacctc
gtggaccgaggaggacgtgaatgacaacacactcttcaagtggatgattttc
aacgggggcgcccccaactgcatcccctgtaaagaaacgtgtgagaacgtgg
actgtggacctgggaaaaaatgccgaatgaacaagaagaacaaaccccgctg
cgtctgcgccccggattgttccaacatcacctggaaggggtccagtctgcggg
10 ctggatgggaaaacctaccgcaatgaatgtgcactcctaaaggcaagatgta
aagagcagccagaactggaagtccagtaccaaggcagatgtaaaaagacttg
tcgggatgttttctgtccaggcagctccacatgtgtggtggaccagaccaat
aatgcctactgtgtgacctgtaatcggatttgcccagagcctgcttcctctg
agcaatatctctgtgggaatgatggagtcacctactccagtgcctgccacct
15 gagaaaggctacctgctgctgggcagatctattggattagcctatgaggga
aagtgtatcaaagcaaagtcctgtgaagatatccagtgcactggtgggaaaa
aatgtttatgggatttcaaggttgggagaggccggtgttcctctgtgatga
gctgtgccctgacagtaagtcggatgagcctgtctgtgccagtgacaatgcc
acttatgccagcgagtgtgccatgaaggaagctgcctgctcctcaggtgtgc
20 tactggaagtaaagcactccggatcttgcaactcatttcggaagacaccga
ggaagaggaggaagatgaagaccaggactacagctttcctatatcttctatt
ctagagtgg (SEQ ID NO: 48)

The following sequence encodes the FST288 polypeptide (SEQ ID NO: 49).

gggaactgctggctccgtcaagcgaagaacggccgctgccaggctcctgtaca
25 agaccgaactgagcaaggaggagtgctgcagcaccggccggctgagcacctc
gtggaccgaggaggacgtgaatgacaacacactcttcaagtggatgattttc
aacgggggcgcccccaactgcatcccctgtaaagaaacgtgtgagaacgtgg
actgtggacctgggaaaaaatgccgaatgaacaagaagaacaaaccccgctg
cgtctgcgccccggattgttccaacatcacctggaaggggtccagtctgcggg
30 ctggatgggaaaacctaccgcaatgaatgtgcactcctaaaggcaagatgta
aagagcagccagaactggaagtccagtaccaaggcagatgtaaaaagacttg
tcgggatgttttctgtccaggcagctccacatgtgtggtggaccagaccaat
aatgcctactgtgtgacctgtaatcggatttgcccagagcctgcttcctctg

agcaatatctctgtgggaatgatggagtcacctactccagtgcctgccacct
gagaaaggctacctgctgctgggcagatctattggattagcctatgagggga
aagtgtatcaaagcaaagtcctgtgaagatatccagtgcactgggaggaaa
aatgtttatgggatttcaagggtgggagaggccgggtgtccctctgtgatga
5 gctgtgccctgacagtaagtcggatgagcctgtctgtgccagtgacaatgcc
acttatgccagcgagtggtgcatgaaggaagctgcctgctcctcaggtgtgc
tactggaagtaaagcactccggatccttgcaac
(SEQ ID NO: 49)

The following sequence encodes the mature FST291 polypeptide (SEQ ID NO: 50).

10 Gggaactgctggctccgtcaagcgaagaacggccgctgccaggtcctgtaca
agaccgaactgagcaaggaggagtgctgcagcaccggccggctgagcacctc
gtggaccgaggaggacgtgaatgacaacacactcttcaagtggatgattttc
aacgggggcgcccccaactgcatcccctgtaaagaaacgtgtgagaacgtgg
actgtggacctgggaaaaaatgccgaatgaacaagaagaacaaaccccgtg
15 cgtctgcgccccggattgttccaacatcacctggaaggggtccagtctgcggg
ctggatgggaaaacctaccgcaatgaatgtgcactcctaaaggcaagatgta
aagagcagccagaactggaagtccagtaccaaggcagatgtaaaaagacttg
tcgggatgttttctgtccaggcagctccacatgtgtggtggaccagaccaat
aatgcctactgtgtgacctgtaatcggatttgcccagagcctgcttcctctg
20 agcaatatctctgtgggaatgatggagtcacctactccagtgcctgccacct
gagaaaggctacctgctgctgggcagatctattggattagcctatgagggga
aagtgtatcaaagcaaagtcctgtgaagatatccagtgcactgggaggaaa
aatgtttatgggatttcaagggtgggagaggccgggtgtccctctgtgatga
gctgtgccctgacagtaagtcggatgagcctgtctgtgccagtgacaatgcc
25 acttatgccagcgagtggtgcatgaaggaagctgcctgctcctcaggtgtgc
tactggaagtaaagcactccggatccttgcaactccatttcgtgg (SEQ
ID NO: 50)

For example, the following sequence (SEQ ID NO: 51) encodes a naturally occurring
human FLRG precursor polypeptide (nucleotides 36-824 of NCBI Reference Sequence
30 NM_005860.2). Nucleotides encoding the signal sequence are underlined.

1 atgcgtcccg gggcgccagg gccactctgg cctctgccct ggggggccct
51 ggcttggggc gtgggcttcg tgagctccat gggctcgggg aaccccgcgc
101 ccgggtggtgt ttgctggctc cagcagggcc aggaggccac ctgcagcctg

151 gtgctccaga ctgatgtcac ccgggcccagag tgctgtgcct ccggcaacat
 201 tgacaccgcc tggccaacc tcaccacccc ggggaacaag atcaacctcc
 251 tcggcttctt gggccttgtc cactgccttc cctgcaaaga ttcgtgcgac
 301 ggctggagat gcggcccggg caaggcgtgc cgcattgctgg ggggcccgcc
 5 351 gcgctgcgag tgcgcgcccg actgctcggg gctcccggcg cggctgcagg
 401 tctgcggctc agacggcgcc acctaccgag acgagtgcca gctgcgcgcc
 451 gcgctgcgcc gcggcccacc ggacctgagc gtcattgtacc ggggcccgtg
 501 ccgcaagtcc tgtgagcacg tgggtgtgcc gcggccacag tcgtgcgtcg
 551 tggaccagac gggcagcgcc cactgcgtgg tgtgtcagac ggcgcctg
 10 601 cctgtgccct ccagccccgg ccaggagctt tgcggcaaca acaacgtcac
 651 ctacatctcc tcgtgccaca tgcgccaggc cacctgcttc ctgggcccgt
 701 ccatcggcgt gcgccacgag ggcagctgag caggcaccac tgaggagccg
 751 ccagggtggtg agtctgcaga agaggaagag aacttcgtg
 (SEQ ID NO: 51)

15 The following sequence (SEQ ID NO: 52) encodes a mature human FLRG polypeptide (nucleotides 114-824 of NCBI Reference Sequence NM_005860.2).

1 atgggctcgg ggaacccccg gccccgggtggt gtttgctggc tccagcaggg
 51 ccaggaggcc acctgcagcc tgggtgctcca gactgatgtc acccgggccc
 101 agtgcgtgac ctccggcaac attgacaccg cctgggtccaa cctcaccac
 20 151 ccggggaaca agatcaacct cctcggcttc ttgggccttg tccactgcct
 201 tccctgcaaa gattcgtgag acggcgtgga gtgcggcccg ggcaaggcgt
 251 gccgcatgct ggggggcccg ccgcgctgag agtgcgcgcc cgactgctcg
 301 gggctcccgg cgcggctgca ggtctgcggc tcagacggcg ccacctaccg
 351 cgacgagtgag gagctgcgag ccgcgctgag ccgcggccac ccggacctga
 25 401 gcgtcatgta ccggggcccg tgcgcgcaagt cctgtgagca cgtggtgtgc
 451 ccgcggccac agtgcgtgag cgtggaccag acgggcagcg cccactgcgt
 501 ggtgtgtcga gcggcgcccct gccctgtgag ctccagcccc ggccaggagc
 551 tttgcggcaa caacaacgtc acctacatct cctcgtgcca catgcgccag
 601 gccacctgct tcttgggccc ctccatcggc gtgcgccacg cgggcagctg
 30 651 cgcaggcacc cctgaggagc cgcaggtgag tgagtctgca gaagaggaag
 701 agaacttcgt g (SEQ ID NO: 52)

For example, the following sequence (SEQ ID NO: 53) encodes a naturally occurring human WFIKKN1 precursor polypeptide (nucleotides 243-1886 of NCBI Reference Sequence NM_053284.2). Nucleotides encoding the signal sequence are underlined.

35 1 atgcccggccc tacgtccact cctgcccgtc ctgctcctcc tccggctgac

51 ctcgggggct ggcttgctgc cagggctggg gagccacccg ggcgtgtgcc
 101 ccaaccagct cagccccaac ctgtgggtgg acgcccagag cacctgtgag
 151 cgcgagtgta gcagggacca ggactgtgcg gctgctgaga agtgctgcat
 201 caacgtgtgt ggactgcaca gctgctggc agcacgcttc cccggcagcc
 5 251 cagctgcgcc gacgacagcg gcctcctgcg agggctttgt gtgcccacag
 301 cagggctcgg actgcgacat ctgggacggg cagcccgtgt gccgctgccg
 351 cgaccgctgt gagaaggagc ccagcttcac ctgcgctcg gacggcctca
 401 cctactacaa ccgctgctat atggacgccg aggcctgcct gcggggcctg
 451 cacctccaca tcgtgccctg caagcacgtg ctcagctggc cgcccagcag
 10 501 cccggggccg ccggagacca ctgcccgcc cacacctggg gccgcgcccg
 551 tgctcctgc cctgtacagc agcccctccc cacaggcggg gcaggttggg
 601 ggtacggcca gcctccactg cgacgtcagc ggccgcccgc cgctgctgt
 651 gacctgggag aagcagagtc accagcgaga gaacctgatc atgcgccctg
 701 atcagatgta tggcaacgtg gtggtcacca gcatcgggca gctggtgctc
 15 751 tacaacgcgc ggcccgaaga cgccggcctg tacacctgca ccgcgcgcaa
 801 cgctgctggg ctgctgcggg ctgacttccc actctctgtg gtccagcgag
 851 agccggccag ggacgcagcc cccagcatcc cagcccggc cgagtgcctg
 901 ccgatgtgc aggcctgcac gggcccact tcccacacc ttgtcctctg
 951 gactacgac ccgcagcggg gcggctgcat gaccttccc gccgctggct
 20 1001 gtgatggggc ggcccgcggc tttgagacct acgaggcatg ccagcaggcc
 1051 tgtgcccgcg gcccggcga cgctgctgctg ctgctgccc tgcagggcc
 1101 ctgccggggc tgggagccgc gctgggccta cagcccgtg ctgcagcagt
 1151 gccatccctt cgtgtacggt ggctgcgagg gcaacggcaa caacttccac
 1201 agccgcgaga gctgcgagga tgcctgccc gtgccgcgca caccgccctg
 25 1251 ccgcgccctg cgctccgga gcaagctggc gctgagcctg tgccgcagcg
 1301 acttcgccat cgtggggcgg ctcacggagg tgctggagga gcccgaggcc
 1351 gccggcggca tcgcccgcgt ggcgctcgag gacgtgctca aggatgacaa
 1401 gatgggctc aagttcttg gcaccaagta cctggagggtg acgctgagtg
 1451 gcatggactg ggctgcccc tgcccaca tgacggcggg cgacgggccc
 30 1501 ctggtcatca tgggtgaggt gcgcatggc gtggccgtgc tggacgccgg
 1551 cagctacgtc cgcgccgcca gcgagaagcg cgtcaagaag atcttggagc
 1601 tgctggagaa gcaggcctgc gagctgctca accgcttcca ggac
 (SEQ ID NO: 53)

The following sequence (SEQ ID NO: 54) encodes a mature human WFIKKN1
 35 polypeptide (nucleotides 300-1886 of NCBI Ref Seq NM_053284.2).

1 gctggcttgc tgccagggt ggggagccac ccgggcgtgt gcccacaacca

51 gctcagcccc aacctgtggg tggacgcca gagcacctgt gagcgcgagt
 101 gtagcagggg ccaggactgt gcggctgctg agaagtgctg catcaacgtg
 151 tgtggactgc acagctgcgt ggcagcacgc tccccggca gccagctgc
 201 gccgacgaca gcggcctcct gcgagggctt tgtgtgcca cagcagggt
 5 251 cggactgcga catctgggac gggcagcccg tgtgccgctg ccgcgaccgc
 301 tgtgagaagg agcccagctt cacctgcgcc tcggacggcc tcacctacta
 351 caaccgctgc tatatggacg ccgaggcctg cctgcggggc ctgcacctcc
 401 acatcgtgcc ctgcaagcac gtgctcagct ggccgcccag cagcccgggg
 451 ccgccggaga ccaactgccc cccacacct ggggccgcgc ccgtgcctcc
 10 501 tgccctgtac agcagcccct cccacaggc ggtgcagggt gggggtacgg
 551 ccagcctcca ctgcgacgtc agcggccgcc cgccgctgc tgtgacctgg
 601 gagaagcaga gtcaccagcg agagaacctg atcatgcgcc ctgatcagat
 651 gtatggcaac gtggtggtca ccagcatcgg gcagctggtg ctctacaacg
 701 cgcgccccga agacgccggc ctgtacacct gcaccgcgcg caacgctgct
 15 751 gggctgctgc gggctgactt cccactctct gtggtccagc gagagccggc
 801 cagggacgca gccccagca tcccagccc ggccgagtgc ctgccgatg
 851 tgcaggcctg cacgggccc acttcccac accttgtcct ctggcactac
 901 gaccgcagc ggggcggctg catgacctc ccggcccgtg gctgtgatgg
 951 ggcgccccgc ggctttgaga cctacgaggc atgccagcag gcctgtgccc
 20 1001 gcggccccgg cgacgcctgc gtgctgcctg ccgtgcaggg cccctgccgg
 1051 ggctgggagc cgcgctgggc ctacagcccg ctgctgcagc agtgccatcc
 1101 cttcgtgtac ggtggctgcg agggcaacgg caacaacttc cacagccgcg
 1151 agagctgcga ggatgcctgc cccgtgccgc gcacaccgcc ctgccgcgcc
 1201 tgccgcctcc ggagcaagct ggcgctgagc ctgtgccgca gcgacttcgc
 25 1251 catcgtgggg cggctcacgg aggtgctgga ggagcccag gccgcccggc
 1301 gcatcgcgcc cgtggcgctc gaggacgtgc tcaaggatga caagatgggc
 1351 ctcaagttct tgggcaccaa gtacctggag gtgacgctga gtggcatgga
 1401 ctgggcctgc ccctgcccc acatgacggc gggcgacggg ccgctggtca
 1451 tcatgggtga ggtgcgcgat ggcgtggccg tgctggacgc cggcagctac
 30 1501 gtccgcgccg ccagcgagaa gcgcgtcaag aagatcttgg agctgctgga
 1551 gaagcaggcc tgcgagctgc tcaaccgctt ccaggac (SEQ ID NO: 54)

For example, the following sequence (SEQ ID NO: 55) encodes a naturally occurring human WFIKKN2 precursor polypeptide (nucleotides 695-2422 of NCBI Reference Sequence NM_175575.5). Nucleotides encoding the signal sequence are underlined.

35 1 atgtgggccc caaggtgtcg ccggttctgg tctcgctggg agcaggtggc
 51 agcgtgctg ctgctgctgc tactgctcgg ggtgccccg cgaagcctgg

101 cgctgccgcc catccgctat tcccacgccg gcatctgccc caacgacatg
 151 aatcccaacc tctgggtgga cgcacagagc acctgcaggc gggagtgtga
 201 gacggaccag gagtgtgaga cctatgagaa gtgctgcccc aacgtatgtg
 251 ggaccaagag ctgctggtgg gcccgctaca tggacgtgaa agggaagaag
 5 301 ggcccagtgg gcatgccc aa ggaggccaca tgtgaccact tcatgtgtct
 351 gcagcagggc tctgagtgtg acatctggga tggccagccc gtgtgttaagt
 401 gcaaagaccg ctgtgagaag gagcccagct ttacctgctc ctcggacggc
 451 ctcacctact ataaccgctg ctacatggat gccgaggcct gctccaaagg
 501 catcacactg gccgttgtaa cctgcccgcta tcaactcacc tggcccaaca
 10 551 ccagcccccc accacctgag accaccatgc accccaccac agcctccccca
 601 gagaccctct agctggacat ggcggcccct gcgctgctca acaaccctgt
 651 gcaccagtcg gtcaccatgg gtgagacagt gagcttctc tgtgatgtgg
 701 tgggccggcc ccggcctgag atcacctggg agaagcagtt ggaggatcgg
 751 gagaatgtgg tcatgcggcc caaccatgtg cgtggcaacg tggtggtcac
 15 801 caacattgcc cagctggtca tctataacgc ccagctgcag gatgctggga
 851 tctacacctg cacggcccgg aacgtggctg gggctcctgag ggctgatttc
 901 ccgctgtcgg tggtcagggg tcatcaggct gcagccacct cagagagcag
 951 cccaatggc acggctttcc cggcggccga gtgcctgaag ccccagaca
 1001 gtgaggactg tggcgaagag cagaccgct ggcacttcca tggccaggcc
 20 1051 aacaactgcc tgaccttcac cttcggccac tgccaccgta acctcaacca
 1101 ctttgagacc tatgaggcct gcatgctggc ctgcatgagc gggccgctgg
 1151 ccgctgacag cctgcccgcc ctgcaggggc cctgcaaagc ctacgcgcct
 1201 cgctgggctt acaacagcca gacgggcccag tgccagtcct ttgtctatgg
 1251 tggctgagag ggcaatggca acaactttga gagccgtgag gcctgtgagg
 25 1301 agtcgtgccc cttccccagg gggaaaccagc gctgtcgggc ctgcaagcct
 1351 cggcagaagc tcgttaccag cttctgtcgc agcgactttg tcatcctggg
 1401 ccgagtctct gagctgaccg aggagcctga ctcgggccgc gccctggtga
 1451 ctgtggatga ggtcctaaag gatgagaaaa tgggcctcaa gttcctgggc
 1501 caggagccat tggaggtcac tctgcttcac gtggactggg catgcccctg
 30 1551 cccaacgtg accgtgagcg agatgccgct catcatcatg ggggaggtgg
 1601 acggcggcat ggccatgctg cgcgccgata gctttgtggg cgcacagagt
 1651 gcccgccggg tcaggaagct tcgtgaggtc atgcacaaga agacctgtga
 1701 cgtcctcaag gagtttcttg gcttgcac (SEQ ID NO: 55)

The following sequence (SEQ ID NO: 56) encodes a mature human WFIKKN2
 35 polypeptide (nucleotides 797-2422 of NCBI Ref Seq NM_175575.5).

1 ctgccgcca tccgctattc ccacgccggc atctgcccc aacgacatgaa

51 tcccaacctc tgggtggacg cacagagcac ctgcaggcgg gagtgtgaga
 101 cggaccagga gtgtgagacc tatgagaagt gctgccccaa cgtatgtggg
 151 accaagagct gcgtggcggc ccgctacatg gacgtgaaag ggaagaaggg
 201 ccagtgggc atgccccagg aggccacatg tgaccacttc atgtgtctgc
 5 251 agcagggctc tgagtgtgac atctgggatg gccagcccgt gtgtaagtgc
 301 aaagaccgct gtgagaagga gccagcctt acctgcgctt cggacggcct
 351 cacctactat aaccgctgct acatggatgc cgaggcctgc tccaaaggca
 401 tcacactggc cgttgtaacc tgccgctatc acttcacctg gcccaacacc
 451 agccccccac cacctgagac caccatgcac cccaccacag cctccccaga
 10 501 gacccttgag ctggacatgg cggcccctgc gctgctcaac aaccctgtgc
 551 accagtcggt caccatgggt gagacagtga gcttcctctg tgatgtgggtg
 601 ggccggcccc ggcttgagat cacctgggag aagcagttgg aggatcggga
 651 gaatgtggtc atgcggccca accatgtgcg tggcaacgtg gtggtcacca
 701 acattgcccc gctggtcac tataacgccc agctgcagga tgctgggatc
 15 751 tacacctgca cggcccggaa cgtggctggg gtcctgaggg ctgatttccc
 801 gctgtcgggtg gtcaggggtc atcaggctgc agccacctca gagagcagcc
 851 ccaatggcac ggctttcccg gcggccgagt gcctgaagcc ccagacagt
 901 gaggactgtg gcgaagagca gaccgctgg cacttcgatg ccagggcaa
 951 caactgcctg accttcacct tcggccactg ccaccgtaac ctcaaccact
 20 1001 ttgagaccta tgaggcctgc atgctggcct gcatgagcgg gccgctggcc
 1051 gcgtgcagcc tgcccgcctt gcagggggccc tgcaaagcct acgcgcctcg
 1101 ctgggcttac aacagccaga cgggccagtg ccagtccttt gtctatggtg
 1151 gctgagaggg caatggcaac aactttgaga gccgtgaggc ctgtgaggag
 1201 tcgtgcccct tccccagggg gaaccagcgc tgtcgggcct gcaagcctcg
 25 1251 gcagaagctc gttaccagct tctgtcgcag cgactttgtc atcctgggcc
 1301 gagtctctga gctgaccgag gagcctgact cgggcccgcg cctggtgact
 1351 gtggatgagg tcctaaagga tgagaaaatg ggcctcaagt tcctgggcca
 1401 ggagccattg gaggtcactc tgcttcacgt ggactgggca tgcccctgcc
 1451 ccaacgtgac cgtgagcgag atgccgctca tcatcatggg ggaggtggac
 30 1501 ggcgcatgg ccatgctgcg cccgatagc tttgtgggcg catcgagtgc
 1551 ccgccgggtc aggaagcttc gtgaggatcat gcacaagaag acctgtgacg
 1601 tcctcaagga gtttcttggc ttgcac (SEQ ID NO: 56)

In certain aspects, the subject nucleic acids encoding follistatin-related polypeptides are further understood to include nucleic acids that are variants of SEQ ID NOs: 47-56.

35 Variant nucleotide sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants; and will, therefore, include

coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 47-56.

In certain embodiments, the disclosure provides isolated or recombinant nucleic acid sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NOs: 47-56. One of ordinary skill in the art will appreciate that nucleic acid sequences complementary to SEQ ID NOs: 47-56, and variants of SEQ ID NO: 47-56 are also within the scope of this disclosure. In further embodiments, the nucleic acid sequences of the disclosure can be isolated, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, nucleic acids of the invention also include nucleotide sequences that hybridize under highly stringent conditions to the nucleotide sequence designated in SEQ ID NOs: 47-56, complement sequence of SEQ ID NOs: 47-56, or fragments thereof.

One of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated nucleic acids that differ from the nucleic acids as set forth in SEQ ID NOs: 47-56 due to degeneracy in the genetic code are also within the scope of the disclosure. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" mutations that do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about

3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this disclosure.

In certain embodiments, the recombinant nucleic acids of the disclosure may be operably linked to one or more regulatory nucleotide sequences in an expression construct. Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the disclosure. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. In a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

In certain aspects, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a follistatin-related polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the follistatin-related polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, and other expression control elements. Exemplary regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding a follistatin-related polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid

phosphatase, e.g., Pho5, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the
5 choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other protein encoded by the vector, such as antibiotic markers, should also be considered.

A recombinant nucleic acid of the disclosure can be produced by ligating the cloned
10 gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of a recombinant follistatin-related polypeptide include plasmids and other vectors. For instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived
15 plasmids for expression in prokaryotic cells, such as *E. coli*.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors
20 are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins
25 in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation of the plasmids and in transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see *Molecular Cloning A*
30 *Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17. In some instances, it may be desirable to express the recombinant polypeptides by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as

pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

5 In certain embodiments, a vector will be designed for production of the subject follistatin-related polypeptides in CHO cells, such as a Pcmv-Script vector (Stratagene, La Jolla, Calif.), pcDNA4 vectors (Invitrogen, Carlsbad, Calif.) and pCI-neo vectors (Promega, Madison, Wisc.). As will be apparent, the subject gene constructs can be used to cause expression of the subject follistatin-related polypeptides in cells propagated in culture, e.g., to produce proteins, including fusion proteins or variant proteins, for purification.

10 This disclosure also pertains to a host cell transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NOs: 19-22) for one or more of the subject follistatin-related polypeptides. The host cell may be any prokaryotic or eukaryotic cell. For example, a follistatin-related polypeptide of the disclosure may be expressed in bacterial cells such as *E. coli*, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

15 Accordingly, the present disclosure further pertains to methods of producing the subject follistatin-related polypeptides. For example, a host cell transfected with an expression vector encoding a follistatin-related polypeptide can be cultured under appropriate conditions to allow expression of the follistatin-related polypeptide to occur. The follistatin-related polypeptide may be secreted and isolated from a mixture of cells and medium
20 containing the follistatin-related polypeptide. Alternatively, the follistatin-related polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The subject follistatin-related polypeptides can be isolated from cell culture medium, host cells, or both, using
25 techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the follistatin polypeptides. In a preferred embodiment, the follistatin-related polypeptide is a fusion protein containing a domain that facilitates its purification.

30 In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant follistatin-related polypeptide, can allow purification of the expressed

fusion protein by affinity chromatography using a Ni²⁺ metal resin. The purification leader sequence can then be subsequently removed by treatment with enterokinase to provide the purified follistatin-related polypeptide (e.g., see Hochuli et al., (1987) *J. Chromatography* 411:177; and Janknecht et al., *PNAS USA* 88:8972).

5 Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining,
10 and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be
15 annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992).

4. Exemplary Therapeutic Uses

In certain embodiments, compositions of the present disclosure, including for example various protein complexes comprising follistatin-related fusion polypeptides disclosed herein,
20 can be used for treating or preventing a disease or condition that is described in this section, including diseases or disorders that are associated with abnormal activity of a follistatin-related polypeptide and/or a follistatin ligand (e.g., myostatin, activins, GDF11). These diseases, disorders or conditions are generally referred to herein as “follistatin-associated conditions.” In certain embodiments, the present disclosure provides methods of treating or
25 preventing an individual in need thereof through administering to the individual a therapeutically effective amount of a follistatin-related fusion polypeptide as described above. These methods are particularly aimed at therapeutic and prophylactic treatments of animals, and more particularly, humans.

As used herein, a therapeutic that “prevents” a disorder or condition refers to a
30 compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated

control sample. The term “treating” as used herein includes amelioration or elimination of the condition once it has been established. In either case, prevention or treatment may be discerned in the diagnosis provided by a physician or other health care provider and the intended result of administration of the therapeutic agent.

5 In general, treatment or prevention of a disease or condition as described in the present disclosure is achieved by administering a follistatin-related polypeptide, or compositions, complexes or combinations comprising such polypeptide, of the present disclosure in an "effective amount". An effective amount of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or
10 prophylactic result. A "therapeutically effective amount" of an agent of the present disclosure may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the agent to elicit a desired response in the individual. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result.

15 Follistatin-ligand complexes play essential roles in tissue growth as well as early developmental processes such as the correct formation of various structures or in one or more post-developmental capacities including sexual development, pituitary hormone production, and creation of muscle. Thus, follistatin-associated conditions include abnormal tissue growth and developmental defects.

20 Exemplary conditions for treatment include neuromuscular disorders (e.g., muscular dystrophy and muscle atrophy), congestive obstructive pulmonary disease (and muscle wasting associated with COPD), muscle wasting syndrome, sarcopenia, and cachexia, adipose tissue disorders (e.g., obesity), type 2 diabetes (NIDDM, adult-onset diabetes), and bone degenerative disease (e.g., osteoporosis). Other exemplary conditions include
25 musculodegenerative and neuromuscular disorders, tissue repair (e.g., wound healing), and neurodegenerative diseases (e.g., amyotrophic lateral sclerosis).

 In certain embodiments, compositions (e.g., follistatin-related fusion proteins) of the invention are used as part of a treatment for a muscular dystrophy. The term “muscular dystrophy” refers to a group of degenerative muscle diseases characterized by gradual
30 weakening and deterioration of skeletal muscles and sometimes the heart and respiratory muscles. Muscular dystrophies are genetic disorders characterized by progressive muscle wasting and weakness that begin with microscopic changes in the muscle. As muscles

degenerate over time, the person's muscle strength declines. Exemplary muscular dystrophies that can be treated with a regimen including the subject follistatin-related polypeptides include: Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSH or FSHD) (also known as Landouzy-Dejerine), myotonic dystrophy (MMD) (also known as Steinert's Disease), oculopharyngeal muscular dystrophy (OPMD), distal muscular dystrophy (DD), congenital muscular dystrophy (CMD).

Duchenne muscular dystrophy (DMD) was first described by the French neurologist Guillaume Benjamin Amand Duchenne in the 1860s. Becker muscular dystrophy (BMD) is named after the German doctor Peter Emil Becker, who first described this variant of DMD in the 1950s. DMD is one of the most frequent inherited diseases in males, affecting one in 3,500 boys. DMD occurs when the dystrophin gene, located on the short arm of the X chromosome, is broken. Since males only carry one copy of the X chromosome, they only have one copy of the dystrophin gene. Without the dystrophin protein, muscle is easily damaged during cycles of contraction and relaxation. While early in the disease muscle compensates by regeneration, later on muscle progenitor cells cannot keep up with the ongoing damage and healthy muscle is replaced by non-functional fibro-fatty tissue.

BMD results from different mutations in the dystrophin gene. BMD patients have some dystrophin, but it is either insufficient in quantity or poor in quality. Having some dystrophin protects the muscles of those with BMD from degenerating as badly or as quickly as those of people with DMD.

For example, recent researches demonstrate that blocking or eliminating function of myostatin (a follistatin ligand) *in vivo* can effectively treat at least certain symptoms in DMD and BMD patients. Thus, the subject follistatin-related fusion polypeptides may act as myostatin inhibitors (antagonists), and constitute an alternative means of blocking the functions of myostatin *in vivo* in DMD and BMD patients.

Similarly, the subject follistatin-related fusion polypeptides provide an effective means to increase muscle mass in other disease conditions that are in need of muscle growth. For example, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease or motor neuron disease) is a chronic, incurable, and unstoppable CNS disorder that attacks the motor neurons, components of the CNS that connect the brain to the skeletal muscles. In ALS, the

motor neurons deteriorate and eventually die, and though a person's brain normally remains fully functioning and alert, the command to move never reaches the muscles. Most people who get ALS are between 40 and 70 years old. The first motor neurons that weaken are those leading to the arms or legs. Those with ALS may have trouble walking, they may drop things, fall, slur their speech, and laugh or cry uncontrollably. Eventually the muscles in the limbs begin to atrophy from disuse. This muscle weakness will become debilitating and a person will need a wheel chair or become unable to function out of bed. Most ALS patients die from respiratory failure or from complications of ventilator assistance like pneumonia, 3-5 years from disease onset.

Increased muscle mass induced by follistatin-related fusion polypeptides might also benefit those suffering from muscle wasting diseases. Myostatin expression correlates inversely with fat-free mass in humans and that increased expression of the *MSTN* gene is associated with weight loss in men with AIDS wasting syndrome. By inhibiting the function of myostatin in AIDS patients, at least certain symptoms of AIDS may be alleviated, if not completely eliminated, thus significantly improving quality of life in AIDS patients.

Cancer anorexia-cachexia syndrome is among the most debilitating and life-threatening aspects of cancer. This syndrome is a common feature of many types of cancer – present in approximately 80% of cancer patients at death – and is responsible not only for a poor quality of life and poor response to chemotherapy but also a shorter survival time than is found in patients with comparable tumors but without weight loss. Cachexia is typically suspected in patients with cancer if an involuntary weight loss of greater than five percent of premonitory weight occurs within a six-month period. Associated with anorexia, wasting of fat and muscle tissue, and psychological distress, cachexia arises from a complex interaction between the cancer and the host. Cancer cachexia affects cytokine production, release of lipid-mobilizing and proteolysis-inducing factors, and alterations in intermediary metabolism. Although anorexia is common, a decreased food intake alone is unable to account for the changes in body composition seen in cancer patients, and increasing nutrient intake is unable to reverse the wasting syndrome. Currently, there is no treatment to control or reverse the cachexic process. Since systemic overexpression of GDF8 in adult mice was found to induce profound muscle and fat loss analogous to that seen in human cachexia syndromes (Zimmers et al., supra), the subject follistatin-related polypeptides may be beneficially used to prevent, treat, or alleviate the symptoms of the cachexia syndrome, where muscle growth is desired.

In other embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, can be used for regulating body fat content in an animal and for treating or preventing conditions related thereto, and particularly, health-compromising conditions related thereto. According to the present invention, to regulate (control) body weight can refer to reducing or increasing body weight, reducing or increasing the rate of weight gain, or increasing or reducing the rate of weight loss, and also includes actively maintaining, or not significantly changing body weight (*e.g.*, against external or internal influences which may otherwise increase or decrease body weight). One embodiment of the present disclosure relates to regulating body weight by administering to an animal (*e.g.*, a human) in need thereof a follistatin-related fusion polypeptides, or combinations of such polypeptides of the disclosure.

In some embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, of the present disclosure can be used for reducing body weight and/or reducing weight gain in an animal, and more particularly, for treating or ameliorating obesity in patients at risk for or suffering from obesity. In another specific embodiment, the present invention is directed to methods and compounds for treating an animal that is unable to gain or retain weight (*e.g.*, an animal with a wasting syndrome). Such methods are effective to increase body weight and/or mass, or to reduce weight and/or mass loss, or to improve conditions associated with or caused by undesirably low (*e.g.*, unhealthy) body weight and/or mass. In addition, disorders of high cholesterol (*e.g.*, hypercholesterolemia or dislipidemia) may be treated with an follistatin-related fusion polypeptides, or combinations of such polypeptides, of the disclosure.

In some embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, of the present disclosure can be used for treating a metabolic disorder such as type II diabetes, metabolic syndrome, hyperadinectionemia, hyperglycemia or hyperinsulinemia.

Fibrosis generally refers to an excessive deposition of both collagen fibers and extracellular matrix combined with a relative decrease of cell number in an organ or tissue. While this process is an important feature of natural wound healing following injury, fibrosis can lead to pathological damage in various tissue and organs including, for example, the lungs, kidneys, liver, bone, muscle, and skin. The role the TGF-beta superfamily in fibrosis has been extensively study. TGF-beta superfamily ligands have been implicated in fibrosis including, for example, activins (*e.g.*, activin A and activin B) and GDF8 [Hedger et al (2013)]

Cytokine and Growth Factor Reviews 24:285-295; Hardy et al. (2015) 93: 567-574; and Cantini et al. (2008) J Sex Med 5:1607-1622]. Therefore, in some embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, of the present disclosure can be used to treat fibrosis, particularly fibrosis-associated disorders and conditions. For example, follistatin-related fusion polypeptides, or combinations of such polypeptides, may be used to treat or prevent one or more of: pulmonary fibrosis, hypersensitivity pneumonitis, idiopathic fibrosis, tuberculosis, pneumonia, cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), emphysema, renal (kidney) fibrosis, renal (kidney) failure, chronic renal (kidney) disease, bone fibrosis, myelofibrosis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, sarcoidosis, granulomatosis with polyangiitis, Peyronie's disease, liver fibrosis, Wilson's disease, glycogen storage diseases (particularly types III, IV, IX, and X), iron-overload, Gaucher disease, Zellweger syndrome, nonalcoholic and alcoholic steatohepatitis, biliary cirrhosis, sclerosing cholangitis, Budd-Chiari syndrome, surgery-associated fibrosis, Crohn's disease, Duputren's contracture, mediastinal fibrosis, nephrogenic fibrosis, retroperitoneal fibrosis, atrial fibrosis, endomyocardial fibrosis, pancreatic fibrosis.

In some embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, of the present disclosure may be used to treat or prevent chronic kidney disease, optionally in combination with one or more supportive therapies for treating chronic kidney disease. In some embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, of the present disclosure may be used to treat or prevent one or more complications (symptoms or manifestations) of chronic kidney disease, optionally in combination with one or more supportive therapies for treating chronic kidney disease. In some embodiments, follistatin-related fusion polypeptides, or combinations of such polypeptides, of the present disclosure may be used to treat or prevent end-stage kidney failure, optionally in combination with one or more supportive therapies for treating end-stage kidney disease. Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function may include feeling generally unwell and experiencing a reduced appetite. Often, chronic kidney disease is diagnosed as a result of screening of people known to be at risk of kidney problems, such as those with high blood pressure or diabetes and those with a blood relative with CKD. This disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia, or pericarditis. Recent

professional guidelines classify the severity of CKD in five stages, with stage 1 being the mildest and usually causing few symptoms and stage 5 being a severe illness with poor life expectancy if untreated. Stage 5 CKD is often called end-stage kidney disease, end-stage renal disease, or end-stage kidney failure, and is largely synonymous with the now outdated terms chronic renal failure or chronic kidney failure; and usually means the patient requires renal replacement therapy, which may involve a form of dialysis, but ideally constitutes a kidney transplant. CKD is initially without specific symptoms and is generally only detected as an increase in serum creatinine or protein in the urine. As the kidney function decreases and various symptoms may manifest as described below. Blood pressure may be increased due to fluid overload and production of vasoactive hormones created by the kidney via the renin-angiotensin system, increasing one's risk of developing hypertension and/or suffering from congestive heart failure. Urea may accumulate, leading to azotemia and ultimately uremia (symptoms ranging from lethargy to pericarditis and encephalopathy). Due to its high systemic circulation, urea is excreted in eccrine sweat at high concentrations and crystallizes on skin as the sweat evaporates ("uremic frost"). Potassium may accumulate in the blood (hyperkalemia with a range of symptoms including malaise and potentially fatal cardiac arrhythmias). Hyperkalemia usually does not develop until the glomerular filtration rate falls to less than 20-25 ml/min/1.73 m², at which point the kidneys have decreased ability to excrete potassium. Hyperkalemia in CKD can be exacerbated by acidemia (which leads to extracellular shift of potassium) and from lack of insulin. Erythropoietin synthesis may be decreased causing anemia. Fluid volume overload symptoms may occur, ranging from mild edema to life-threatening pulmonary edema. Hyperphosphatemia, due to reduced phosphate excretion, may occur generally following the decrease in glomerular filtration. Hyperphosphatemia is associated with increased cardiovascular risk, being a direct stimulus to vascular calcification. Hypocalcemia may manifest, which is generally caused by stimulation of fibroblast growth factor-23. Osteocytes are responsible for the increased production of FGF23, which is a potent inhibitor of the enzyme 1-alpha-hydroxylase (responsible for the conversion of 25-hydroxycholecalciferol into 1,25 dihydroxyvitamin D₃). Later, this progresses to secondary hyperparathyroidism, renal osteodystrophy, and vascular calcification that further impairs cardiac function. Metabolic acidosis (due to accumulation of sulfates, phosphates, uric acid etc.) may occur and cause altered enzyme activity by excess acid acting on enzymes; and also increased excitability of cardiac and neuronal membranes by the promotion of hyperkalemia due to excess acid (acidemia). Acidosis is also due to decreased capacity to generate enough ammonia from the cells of the proximal tubule. Iron

deficiency anemia, which increases in prevalence as kidney function decreases, is especially prevalent in those requiring haemodialysis. It is multifactorial in cause, but includes increased inflammation, reduction in erythropoietin, and hyperuricemia leading to bone marrow suppression. People with CKD suffer from accelerated atherosclerosis and are more likely to develop cardiovascular disease than the general population. Patients afflicted with CKD and cardiovascular disease tend to have significantly worse prognoses than those suffering only from the latter.

As used herein, “in combination with”, “combinations of”, or “conjoint administration” refers to any form of administration such that additional therapies (e.g., second, third, fourth, etc.) are still effective in the body (e.g., multiple compounds are simultaneously effective in the patient, which may include synergistic effects of those compounds). Effectiveness may not correlate to measurable concentration of the agent in blood, serum, or plasma. For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially, and on different schedules. Thus, an individual who receives such treatment can benefit from a combined effect of different therapies. One or more follistatin-related fusion polypeptides, or combinations of such polypeptides of the disclosure can be administered concurrently with, prior to, or subsequent to, one or more other additional agents or supportive therapies. In general, each therapeutic agent will be administered at a dose and/or on a time schedule determined for that particular agent. The particular combination to employ in a regimen will take into account compatibility of the antagonist of the present disclosure with the therapy and/or the desired.

5. Pharmaceutical Compositions

In certain embodiments, compounds (e.g., follistatin-related polypeptides) of the present invention are formulated with a pharmaceutically acceptable carrier. For example, a follistatin-related polypeptide can be administered alone or as a component of a pharmaceutical formulation (i.e., a therapeutic composition). The subject compounds may be formulated for administration in any convenient way for use in human or veterinary medicine.

In certain embodiments, the therapeutic method of the invention includes administering the composition topically, systemically, locally, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of

course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to a target tissue site (e.g., bone, cartilage, muscle, fat or neurons), for example, a site having tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than the follistatin-related polypeptides, which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the subject compounds (e.g., follistatin-related polypeptides) in the methods of the invention.

In certain embodiments, compositions of the present invention may include a matrix capable of delivering one or more therapeutic compounds (e.g., follistatin-related polypeptides) to a target tissue site, providing a structure for the developing tissue and optimally capable of being resorbed into the body. For example, the matrix may provide slow release of the follistatin-related polypeptides. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the subject compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid and polyanhydrides. Other potential materials are biodegradable and biologically well defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are non-biodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above-mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

In certain embodiments, methods of the invention can be administered for orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an

agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.

In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), one or more therapeutic compounds of the present invention may be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution 10 retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical 15 compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols.

Liquid dosage forms for oral administration include pharmaceutically acceptable 20 emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, 25 castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents 30 such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Certain compositions disclosed herein may be administered topically, either to skin or to mucosal membranes. The topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone, dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.

Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required. The ointments, pastes, creams and gels may contain, in addition to a subject compound of the invention (e.g., a follistatin-related polypeptide), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a subject compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

In certain embodiments, pharmaceutical compositions suitable for parenteral administration may comprise one or more follistatin-related polypeptides in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example,

by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the invention may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of
5 microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption, such as aluminum
10 monostearate and gelatin.

It is understood that the dosage regimen will be determined by the attending physician, considering various factors that modify the action of the subject compounds of the invention (e.g., follistatin-related polypeptides). The various factors will depend upon the disease to be treated.

15 In certain embodiments, the present invention also provides gene therapy for the *in vivo* production of follistatin-related polypeptides or other compounds disclosed herein. Such therapy would achieve its therapeutic effect by introduction of the follistatin-related polynucleotide sequences into cells or tissues having the disorders as listed above. Delivery of follistatin-related polynucleotide sequences can be achieved using a recombinant
20 expression vector such as a chimeric virus or a colloidal dispersion system. Preferred for therapeutic delivery of follistatin-related polynucleotide sequences is the use of targeted liposomes.

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus.
25 Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer
30 or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target-specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody. Those

of skill in the art will recognize that specific polynucleotide sequences can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the follistatin-related polynucleotide. In one preferred embodiment, the vector is targeted to bone, cartilage, muscle or neuron cells/tissues.

5 Alternatively, tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

 Another targeted delivery system for follistatin-related polynucleotides is a colloidal
10 dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous
15 interior and be delivered to cells in a biologically active form (see e.g., Fraley, et al., Trends Biochem. Sci., 6:77, 1981). Methods for efficient gene transfer using a liposome vehicle, are known in the art, see e.g., Mannino, et al., Biotechniques, 6:682, 1988. The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical
20 characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

 Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebroside, and gangliosides. Illustrative phospholipids include egg
25 phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine. The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and organelle-specificity and is known in the art.

EXEMPLIFICATION

30 The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of

certain embodiments and embodiments of the present invention, and are not intended to limit the invention.

Example 1. Generation of a single-arm WFIKKN2 polypeptide fusion protein

5 Applicants generated a soluble asymmetric Fc fusion protein in which native full-length human WFIKKN2 polypeptide was attached through a linker to one of two human G1Fc chains.

A methodology for promoting formation of WFIKKN2-Fc heteromeric complexes, as opposed to WFIKKN2-Fc homodimeric complexes, is to introduce alterations in the amino acid sequence of the Fc domains to guide the formation of asymmetric heteromeric
10 complexes. Many different approaches to making asymmetric interaction pairs using Fc domains are described in this disclosure.

In one approach, illustrated in the polypeptide sequences of SEQ ID NOs: 57 and 58, one Fc domain is altered to introduce cationic amino acids at the interaction face, while the
15 other Fc domain is altered to introduce anionic amino acids at the interaction face. In this example, correct pairing of the two polypeptide chains is promoted through a charge-based mechanism by substituting lysine residues at two positions (underlined) in WFIKKN2-G1Fc(E134K/D177K) (SEQ ID NO: 57) and aspartate residues at two positions (underlined) in G1Fc(K170D/K187D) (SEQ ID NO: 58). An optional N-terminal extension of 13 amino
20 acids (underlined) is included on the short chain (SEQ ID NO: 58) to facilitate disulfide bond formation by the cysteine at position 4.

```

1   LPPIRYSHAG ICPNDMNPNL WVDAQSTCRR ECETDQECET YEKCCPNVCG
51  TKSCVAARYM DVKGKKGKGPVG MPKEATCDHF MCLQQGSECD IWDGQPVCKC
101 KDRCEKEPSF TCASDGLTTY NRCYMDAEAC SKGITLAVVT CRYHFTWPNT
25  151  SPPPPETTMH PTTASPETPE LDMAAPALLN NPVHQSVTMG ETVSFLCDVV
201  GRPRPEITWE KQLEDRENVV MRPNHVRGNV VVTNIAQLVI YNAQLQDAGI
251  YTCTARNVAG VLRADFPLSV VRGHQAAATS ESSPNGTAFP AADECLKPPDS
301  EDCGEEQTRW HFDAQANNCL TFTFGHCHRN LNHFETYEAC MLACMSGPLA
351  ACSLPALQGP CKAYAPRWAY NSQTGQCQSF VYGGCEGNGN NFESREACEE
30  401  SCPFPRGNQR CRACKPRQKL VTSFCRSDFV ILGRVSELTE EPDSGRALVT
451  VDEVLKDEKM GLKFLGQEPL EVTLLHVDWA CPCPNVTVSE MPLIIMGEVD
501  GGMAMLRPDS FVGASSARRV RKLREVMHKK TCDVLKEFLG LHTGGGGSGG
551  GGSGGGGGSGG GGSTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV
601  TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL

```

651 HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRKEMT
 701 KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLK SDGSFFLYSK
 751 LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK

(SEQ ID NO: 57)

5 -13 SNTKVDKRVT GGG
 1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSREEMTKNQ VSLTCLVKGF
 151 YPSDIAVEWE SNGQPENNYD TTPPVLDSDG SFFLYSDLTV DKSRWQQGNV
 10 201 FSCSVMHEAL HNHYTQKSL S LSPGK (SEQ ID NO: 58)

Corresponding nucleic acid sequences for the mature (processed) forms of these variants are SEQ ID NOs: 59, 60.

1 CTGCCGCCCA TCCGCTATTC CCACGCCGGC ATCTGCCCCA ACGACATGAA
 51 TCCCAACCTC TGGGTGGACG CACAGAGCAC CTGCAGGCGG GAGTGTGAGA
 15 101 CGGACCAGGA GTGTGAGACC TATGAGAAGT GCTGCCCCAA CGTATGTGGG
 151 ACCAAGAGCT GCGTGGCGGC CCGCTACATG GACGTGAAAG GGAAGAAGGG
 201 CCCAGTGGGC ATGCCCAAGG AGGCCACATG TGACCACTTC ATGTGTCTGC
 251 AGCAGGGCTC TGAGTGTGAC ATCTGGGATG GCCAGCCCGT GTGTAAGTGC
 301 AAAGACCGCT GTGAGAAGGA GCCCAGCTTT ACCTGCGCCT CGGACGGCCT
 20 351 CACCTACTAT AACCGCTGCT ACATGGATGC CGAGGCCTGC TCCAAAGGCA
 401 TCACACTGGC CGTTGTAACC TGCCGCTATC ACTTCACCTG GCCCAACACC
 451 AGCCCCCAC CACCTGAGAC CACCATGCAC CCCACCACAG CCTCCCCAGA
 501 GACCCCTGAG CTGGACATGG CGGCCCTGC GCTGCTCAAC AACCTGTGTC
 551 ACCAGTCGGT CACCATGGGT GAGACAGTGA GCTTCCTCTG TGATGTGGTG
 25 601 GGCCGGCCCC GGCCTGAGAT CACCTGGGAG AAGCAGTTGG AGGATCGGGA
 651 GAATGTGGTC ATGCGGCCCA ACCATGTGCG TGGCAACGTG GTGGTCACCA
 701 ACATTGCCCA GCTGGTCATC TATAACGCC AGCTGCAGGA TGCTGGGATC
 751 TACACCTGCA CGGCCCGGAA CGTGGCTGGG GTCCTGAGGG CTGATTTCCC
 801 GCTGTCGGTG GTCAGGGGTC ATCAGGCTGC AGCCACCTCA GAGAGCAGCC
 30 851 CCAATGGCAC GGCTTTCCCG GCGGCCGAGT GCCTGAAGCC CCCCACAGT
 901 GAGGACTGTG GCGAAGAGCA GACCCGCTGG CACTTCGATG CCCAGGCCAA
 951 CAACTGCCTG ACCTTCACCT TCGGCCACTG CCACCGTAAC CTCAACCACT
 1001 TTGAGACCTA TGAGGCCTGC ATGCTGGCCT GCATGAGCGG GCCGCTGGCC
 1051 GCGTGCAGCC TGCCCCCCCT GCAGGGGCC TGCAAAGCCT ACGCGCCTCG
 35 1101 CTGGGCTTAC AACAGCCAGA CGGGCCAGTG CCAGTCCTTT GTCTATGGTG
 1151 GCTGCGAGGG CAATGGCAAC AACTTTGAGA GCCGTGAGGC CTGTGAGGAG

1201 TCGTGCCCT TCCCCAGGGG GAACCAGCGC TGTCGGGCCT GCAAGCCTCG
 1251 GCAGAAGCTC GTTACCAGCT TCTGTGCGAG CACTTTGTG ATCCTGGGCC
 1301 GAGTCTCTGA GCTGACCGAG GAGCCTGACT CGGGCCGCGC CCTGGTACT
 1351 GTGGATGAGG TCCTAAAGGA TGAGAAAATG GGCCTCAAGT TCCTGGGCCA
 5 1401 GGAGCCATTG GAGGTCACCTC TGCTTCACGT GGACTGGGCA TGCCCCTGCC
 1451 CCAACGTGAC CGTGAGCGAG ATGCCGCTCA TCATCATGGG GGAGGTGGAC
 1501 GGCGGCATGG CCATGCTGCG CCCCAGATAGC TTTGTGGGCG CATCGAGTGC
 1551 CCGCCGGGTC AGGAAGCTTC GTGAGGTCAT GCACAAGAAG ACCTGTGACG
 1601 TCCTCAAGGA GTTTCTTGGC TTGCACACCG GTGGTGGAGG TTCTGGAGGT
 10 1651 GGAGGAAGTG GTGGAGGTGG TTCTGGAGGT GGTGGAAGTA CTCACACATG
 1701 CCCACCGTGC CCAGCACCTG AACTCCTGGG GGGACCGTCA GTCTTCCTCT
 1751 TCCCCCAA AAAACCAAGGAC ACCCTCATGA TCTCCCGGAC CCCTGAGGTC
 1801 ACATGCGTGG TGGTGGACGT GAGCCACGAA GACCCTGAGG TCAAGTTCAA
 1851 CTGGTACGTG GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG
 15 1901 AGGAGCAGTA CAACAGCACG TACCGTGTGG TCAGCGTCCT CACCGTCCTG
 1951 CACCAGGACT GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA
 2001 AGCCCTCCCA GCCCCATCG AGAAAACCAT CTCCAAAGCC AAAGGCAGC
 2051 CCCGAGAACC ACAGGTGTAC ACCCTGCCCC CATCCCGGAA GGAGATGACC
 2101 AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT ATCCCAGCGA
 20 2151 CATCGCCGTG GAGTGGGAGA GCAATGGGCA GCCGGAGAAC AACTACAAGA
 2201 CCACGCCTCC CGTGCTGAAG TCCGACGGCT CCTTCTTCCT CTATAGCAAG
 2251 CTCACCGTGG ACAAGAGCAG GTGGCAGCAG GGGAACGTCT TCTCATGCTC
 2301 CGTGATGCAT GAGGCTCTGC ACAACCACTA CACGCAGAAG AGCCTCTCCC
 2351 TGTCTCCGGG TAAA (SEQ ID NO: 59)
 25
 1 AGCAACACCA AGGTGGACAA GAGAGTTACC GGTGGTGGAA CTCACACATG
 51 CCCACCGTGC CCAGCACCTG AACTCCTGGG GGGACCGTCA GTCTTCCTCT
 101 TCCCCCAA AAAACCAAGGAC ACCCTCATGA TCTCCCGGAC CCCTGAGGTC
 30 151 ACATGCGTGG TGGTGGACGT GAGCCACGAA GACCCTGAGG TCAAGTTCAA
 201 CTGGTACGTG GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG
 251 AGGAGCAGTA CAACAGCACG TACCGTGTGG TCAGCGTCCT CACCGTCCTG
 301 CACCAGGACT GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA
 351 AGCCCTCCCA GCCCCATCG AGAAAACCAT CTCCAAAGCC AAAGGCAGC
 35 401 CCCGAGAACC ACAGGTGTAC ACCCTGCCCC CATCCCGGGA GGAGATGACC
 451 AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT ATCCCAGCGA
 501 CATCGCCGTG GAGTGGGAGA GCAATGGGCA GCCGGAGAAC AACTACGACA
 551 CCACGCCTCC CGTGCTGGAC TCCGACGGCT CCTTCTTCCT CTATAGCGAC

601 CTCACCGTGG ACAAGAGCAG GTGGCAGCAG GGAACGTCT TCTCATGCTC
 651 CGTGATGCAT GAGGCTCTGC ACAACCACTA CACGCAGAAG AGCCTCTCCC
 701 TGTCTCCGGG TAAA (SEQ ID NO: 60)

The proteins of SEQ ID NO: 57 and SEQ ID NO: 58 may be co-expressed and
 5 purified from a CHO cell line, to give rise to a heteromeric complex comprising WFIKKN2-
 Fc.

In another approach to promote the formation of heteromultimer complexes using
 asymmetric Fc fusion proteins the Fc domains are altered to introduce complementary
 hydrophobic interactions and an additional intermolecular disulfide bond as illustrated in the
 10 polypeptide sequences of SEQ ID NOs: 71 and 72.

1 LPPIRYSHAG ICPNDMNPNL WVDAQSTCRR ECETDQECET YEKCCPNVCG
 51 TKSCVAARYM DVKGKKGKPVG MPKEATCDHF MCLQQGSECD IWDGQPVCKC
 101 KDRCEKEPSF TCASDGLTYT NRCYMDAEAC SKGITLAVVT CRYHFTWPNT
 151 SPPPPETTMH PTTASPETPE LDMAAPALLN NPVHQSVTMG ETVSFLCDVV
 15 201 GRPRPEITWE KQLEDRENVV MRPNHVRGNV VVTNIAQLVI YNAQLQDAGI
 251 YTCTARNVAG VLRADFPLSV VRGHQAAATS ESSPNGTAFP AAECCLKPPDS
 301 EDCGEEQTRW HFDAQANNCL TFTFGHCHRN LNHFETYEAC MLACMSGPLA
 351 ACSLPALQGP CKAYAPRWAY NSQTGQCQSF VYGGCEGNGN NFESREACEE
 401 SCPFPRGNQR CRACKPRQKL VTSFCRSDFV ILGRVSELTE EPDSGRALVT
 20 451 VDEVLKDEKM GLKFLGQEPL EVTLLHVDWA CPCPNVTVSE MPLIIMGEVD
 501 GGMAMLRPDS FVGASSARRV RKLREVMHKK TCDVLKEFLG LHTGGGTHTC
 601 PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFNW
 701 YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKAL
 801 PAPIEKTISK AKGQPREPQV YTLPPCREEM TKNQVSLWC₁L VKGFYPSDIAV
 25 901 EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMHE
 1001 ALHNHYTQKS LSLSPGK (SEQ ID NO: 71)

To promote formation of the heterodimer rather than either of the possible
 homodimeric complexes, two amino acid substitutions (replacing a serine with a cysteine and
 a threonine with a tryptophan) can be introduced into the Fc domain of the fusion protein as
 30 indicated by double underline above. The amino acid sequence of SEQ ID NO: 71 may
 optionally be provided with lysine (K) removed from the C-terminus.

The complementary form of Fc fusion polypeptide (SEQ ID NO: 72) is as follows and
 may optionally be provided with lysine (K) removed from the C-terminus.

-13 SNTKVDKRVT GGG
 1 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
 51 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
 101 VSNKALPAPI EKTISKAKGQ PREPQVCTLP PSREEMTKNQ VSLSCAVKGF
 5 151 YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLVSKLTV DKSRWQQGNV
 201 FSCSVMHEAL HNHYTQKSL S LSPGK (SEQ ID NO: 72)

To guide heterodimer formation with the polypeptide of SEQ ID NOs: 71 above, four amino acid substitutions can be introduced into the Fc polypeptide as indicated by double underline above. The amino acid sequence of SEQ ID NO: 72 may optionally be provided
 10 with lysine (K) removed from the C-terminus.

The proteins of SEQ ID NO: 71 and SEQ ID NO: 72 may be co-expressed and purified from a CHO cell line, to give rise to a heteromeric complex comprising WFIKKN2-Fc.

The present disclosure provides for expression of follistatin-related polypeptides in
 15 cells with, for example, one of the following leader sequences:

Native human follistatin leader: MVRARHQPGGLCLLLLLLLCQFMEDRSAQA
 (SEQ ID NO: 61)

Native human FLRG leader: MRPGAPGPLWPLPWGALAWAVGFVSS
 (SEQ ID NO: 62)

20 Native human WFIKKN1 leader: MPALRPLLPLLLLLLRLTSG
 (SEQ ID NO: 63)

Native human WFIKKN2 leader: MWAPRCRRFWSRWEQVAALLLLLLLLLVPPRSLA
 (SEQ ID NO: 64)

25 Tissue plasminogen activator (TPA): MDAMKRGLCCVLLLCGAVFVSP
 (SEQ ID NO: 65)

Honey bee melittin (HBML): MKFLVNVALVFMVVYISYIYA
 (SEQ ID NO: 66)

Selected follistatin-related polypeptide variants incorporate the TPA leader and are fused to a G1Fc domain (SEQ ID NO: 39, 40, 41, 42, 43, 44, 45, or 46) with or without an
 30 optional linker to form a long chain. A short chain comprising a complementary G1Fc domain (SEQ ID NO: 39, 40, 41, 42, 43, 44, 45, or 46) that promotes pairing with the long

chain also incorporates the TPA leader. Constructs were coexpressed in COS or CHO cells and purified from conditioned media by filtration and protein A chromatography. Purity of samples for reporter gene assays was evaluated by SDS-PAGE and Western blot analysis.

Two variants incorporating native full-length human WFIKKN2 polypeptide were generated for direct comparison with the single-arm WFIKKN2-hG1Fc fusion protein produced by coexpression. The first variant was a *dual-arm* WFIKKN2-hG1Fc fusion protein and the second variant was a *single-chain* WFIKKN2 polypeptide attached at its C-terminus to a His6 tag.

Applicants transiently transfected COS cells with constructs encoding single-arm WFIKKN2-hG1Fc and dual-arm WFIKKN2-hG1Fc. CHO cells were used to stably express WFIKKN2-His6. A UCOE™-based construct encoding WFIKKN2-His6 was stably transfected into a CHO cell line, clones were selected with methotrexate, and any clones that formed colonies were then pooled. No gene amplification was performed since it is difficult to amplify UCOE™ pools while maintaining stability of expression. Instead of dilution cloning, high-expressing pools were identified and used for generating WFIKKN2-His6.

Purification of Fc-containing constructs was achieved with a variety of techniques, including, for example, filtration of conditioned media, followed by protein A chromatography, elution with glycine buffer (pH 3.0), sample neutralization, and size-exclusion chromatography. Purity of Fc-containing constructs was evaluated by analytical size-exclusion chromatography and SDS-PAGE.

Purification of WFIKKN2-His6 was achieved using a variety of techniques, including, for example, diafiltration of conditioned media, followed by nickel-nitrilotriacetic acid (Qiagen) agarose affinity chromatography, elution with imidazole buffer, and dialysis against PBS. Purity of samples was evaluated for all constructs by analytical size-exclusion chromatography and SDS-PAGE. Analysis of mature protein confirmed the expected N-terminal sequence for WFIKKN2-His6.

Example 2. Potency of a single-arm WFIKKN2 polypeptide fusion protein

A reporter gene assay in A204 rhabdomyosarcoma cells was used to evaluate the ability of full-length human WFIKKN2 polypeptide variants to inhibit myostatin signaling. This assay is based on a human rhabdomyosarcoma cell line transfected with a pGL3(CAGA)12 reporter plasmid [Dennler et al (1998) EMBO 17:3091-3100] as well as a

control Renilla reporter plasmid (pRL-CMV) to normalize for transfection efficiency. The CAGA12 motif is present in TGF β -responsive genes such as plasminogen activator inhibitor type 1, so this vector is of general use for factors signaling through Smad2 and Smad3.

On the first day of the assay, A204 cells (ATCC[®] HTB-82) were distributed in 48-well plates at 10⁵ cells per well and incubated overnight in McCoy's 5A growth medium (Life Technologies) supplemented with 10% FBS. All incubations were at 37°C with 5% CO₂ unless otherwise noted. On the second day, a solution containing 10 μ g pGL3(CAGA)12, 0.1 μ g pRL-CMV, 30 μ l X-tremeGENE 9 (Roche Diagnostics), and 970 μ l OptiMEM (Life Technologies) was incubated for 30 minutes at room temperature prior to adding to assay buffer (McCoy's 5A medium + 0.1% bovine serum albumin) and applying to the plated cells (500 μ l/well) for an overnight incubation. On the third day, medium was removed, and cells were incubated for 6 h with a mixture of ligands and inhibitors prepared as described below.

To evaluate the ability of WFIKKN2 constructs to inhibit myostatin signaling, a serial dilution of each test article (two replicates each) was made in a 48-well plate in assay buffer to a final volume of 200 μ l. An equal volume of myostatin (R&D Systems, final concentration of 32 ng/ml) in assay buffer was then added. The test solutions were incubated for 30 minutes prior to adding 250 μ l of this mixture to each well of the 48-well plate of transfected A204 cells. After incubation with test solutions for 6 h, cells were rinsed with phosphate-buffered saline, then lysed with passive lysis buffer (Promega E1941) and stored overnight at -70°C. On the fourth and final day, the plates were warmed to room temperature with gentle shaking. Cell lysates were transferred to a 96-well chemiluminescence plate and analyzed in a luminometer with reagents from a Dual-Luciferase Reporter Assay system (Promega E1980). The luciferase activity of the experimental reporter was normalized to the luciferase activity obtained with the Renilla control reporter.

WFIKKN2 polypeptide constructs differed markedly in their ability to inhibit signaling by myostatin. As shown in the table below, single-chain WFIKKN2-His6 and single-arm WFIKKN2-G1Fc potently inhibited myostatin signaling, with IC₅₀ values in the low nanomolar range. In contrast, dual-arm WFIKKN2-G1Fc did not show any reduction in myostatin signaling over the range of concentrations tested, which suggests that the IC₅₀ value for this construct would be at least 100 nM. Thus, the potency of myostatin inhibition with single-arm WFIKKN2-G1Fc was substantially higher than that of a G1Fc fusion protein comprising dual WFIKKN2 arms.

Construct	IC ₅₀ (nM)	Half-life in Mouse (h)
Single-chain WFIKKN2-His6	1.4	~ 2.5
Single-arm WFIKKN2-G1Fc	2.9	~ 110
Dual-arm WFIKKN2-G1Fc	> 100	ND

ND, not determined

Elimination pharmacokinetics of single-chain WFIKKN2-His6 and single-arm WFIKKN2-G1Fc were studied in separate experiments conducted in mice. Concentrations of single-chain WFIKKN2-His6 in mouse serum samples after subcutaneous administration of a single dose were measured by ELISA with a commercial anti-His6 antibody (abcam[®] ab18184). Concentrations of single-arm WFIKKN2-G1Fc after subcutaneous administration of a single dose were measured by ELISA with a commercial anti-human IgG1 antibody (Binding Site Immunologicals AP006). As indicated in the table above, the half-life of single-chain WFIKKN2-His6 protein in mice was approximately 2.5 hours (data not shown), whereas the half-life of single-arm WFIKKN2-G1Fc fusion protein in mice (n = 3) was more than 100 hours (data not shown), which would predict that this molecule will have a pharmacologically useful serum half-life in humans of 10-20 days. Thus, by utilizing a heterodimeric or asymmetric approach to generating a single-arm WFIKKN2 construct, applicants were able to combine the desirable ligand binding activity of the single chain (native) protein with the desirable serum half-life of a traditional homodimeric Fc fusion protein.

Together, these results indicate that single-arm WFIKKN2-G1Fc could be a useful therapeutic agent. Beyond this example, applicants predict that other asymmetric fusion proteins comprising single-arm follistatin-related polypeptides will also display more potent inhibition of ligand signaling than their dual-arm counterparts while conferring ease of purification and a serum half-life that is typical for a homodimeric Fc fusion protein construct.

INCORPORATION BY REFERENCE

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually
5 indicated to be incorporated by reference.

While specific embodiments of the subject matter have been discussed, the above specification is illustrative and not restrictive. Many variations will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of
10 equivalents, and the specification, along with such variations.

We claim:

1. A protein complex comprising a first polypeptide covalently or non-covalently associated with a second polypeptide, wherein:
 - a. the first polypeptide comprises the amino acid sequence of a follistatin-related polypeptide and the amino acid sequence of a first member of an interaction pair; and
 - b. the second polypeptide comprises the amino acid sequence of a second member of the interaction pair, and wherein the second polypeptide does not comprise a follistatin-related polypeptide.
2. The protein complex of claim 1, wherein the amino acid sequence of a follistatin-related polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of any of SEQ ID Nos: 1-33.
3. The protein complex of claim 1 or 2, wherein the first polypeptide comprises a linker polypeptide positioned between the amino acid sequence of the follistatin-related polypeptide and the amino acid sequence of the first member of the interaction pair.
4. The protein complex of any one of claims 1-3, wherein the first member of the interaction pair comprises a constant domain of an immunoglobulin and wherein the second member of the interaction pair comprises a constant domain of an immunoglobulin.
5. The protein complex of any one of claims 1-4, wherein the first member of the interaction pair comprises an Fc domain of an immunoglobulin and wherein the second member of the interaction pair comprises a constant domain of an immunoglobulin.
6. The protein complex of any one of claims 1-5, wherein the first member of the interaction pair comprises an amino acid sequence that is an Fc domain of an IgG1, IgG2, IgG3 or IgG4.

7. The protein complex of claim 5, wherein the first member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs: 34-46.
- 5
8. The protein complex of any one of claims 1-7, wherein the second member of the interaction pair comprises an amino acid sequence that is an Fc domain of an IgG1, IgG2, IgG3 or IgG4.
- 10
9. The protein complex of any one of claims 1-8, wherein the second member of the interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs: 34-46.
10. The protein complex of any one of claims 1-9, wherein the first member of the interaction pair associates covalently or non-covalently with the second member of the interaction pair to form a dimeric protein complex.
- 15
11. The protein complex of any one of claims 1-10, wherein the interaction pair is an asymmetric interaction pair.
- 20
12. The protein complex of claim 11, wherein the first member of the asymmetric interaction pair comprises a first modified constant domain of an IgG and wherein the second member of the asymmetric interaction pair comprises a second modified constant domain of an IgG, and wherein the first and second members of the asymmetric interaction pair associate to form a heterodimeric complex.
- 25
13. The protein complex of claim 11, wherein the first member of the asymmetric interaction pair comprises a first modified Fc portion of IgG and wherein the second member of the asymmetric interaction pair comprises a second modified Fc portion of an IgG, and wherein the first and second members of the asymmetric interaction pair associate to form a heterodimeric complex.
- 30

14. The protein complex of claim 13, wherein the first Fc portion of an IgG comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group: SEQ ID NOs 34-46, and wherein the second Fc portion of an IgG comprises an amino acid sequence that is different from the amino acid sequence of the first Fc portion of an IgG and that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group SEQ ID NOs 34-46.
15. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:39
16. The protein complex of any one of claims 13-15, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 40.
17. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:40.
18. The protein complex of any one of claims 13, 14, or 17 wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 39.
19. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:41.
20. The protein complex of any one of claims 13, 14, or 19, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that

is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 42.

21. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:42.
22. The protein complex of any one of claims 13, 14, or 21, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 41.
23. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:43.
24. The protein complex of any one of claims 13, 14, or 23, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 44.
25. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:44.
26. The protein complex of any one of claims 13, 14, or 25, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 43.

27. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:45.
- 5
28. The protein complex of any one of claims 13, 14, or 27, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 46.
- 10
29. The protein complex of claim 13 or 14, wherein the first member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:46.
- 15
30. The protein complex of any one of claims 13, 14, or 29, wherein the second member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 45.
- 20
31. The protein complex of any of claims 1-11, wherein the interaction pair is an unguided interaction pair.
32. The protein complex of claim 31, wherein the first member of the unguided interaction pair associates covalently or non-covalently with the second member of the interaction pair to form a dimeric complex.
- 25
33. The protein complex of claim 31 or 32, wherein the first member of the unguided interaction pair has the same amino acid sequence as the second member of the unguided interaction pair.
- 30
34. The protein complex of any of claims 1-33 wherein the second polypeptide comprises the amino acid sequence of a second member of the interaction pair,

and wherein the second polypeptide does not comprise any other amino acid sequence that confers a substantial biological activity.

- 5 35. The protein complex of any of claims 1-34 wherein the second polypeptide consists of the amino acid sequence of a second member of the interaction pair, provided that the second polypeptide may comprise an additional 1-50, 1-40, 1-30, 1-20 or 1-10 amino acids fused to the C-terminus, the N-terminus or both the C- and N-termini of the amino acid sequence of the second member of the interaction pair.
- 10 36. The protein complex of claim 35, wherein the additional amino acids confer no substantial biological activity.
- 15 37. The protein complex of any of claims 1-36, wherein the protein complex binds to one or more ligands selected from: GDF8, GDF11, activin A, activin B, activin C or activin E with a K_D of greater than or equal to 10^{-9} , 10^{-10} , 10^{-11} , or 10^{-12} .
- 20 38. The protein complex of any of claims 1-36, wherein the protein complex inhibits in a cell-based assay signaling by one or more ligands selected from: GDF8, GDF11, activin A, activin B, activin C or activin E.
- 25 39. The protein complex of any of claims 1-38, wherein the protein complex exhibits a serum half-life in a mouse of at least 6, 12, 24, 36, 48 or 72 hours.
40. The protein complex of any of claims 1-38, wherein the protein complex exhibits a serum half-life in a human of at least 6, 8, 10, or 12 days.
- 30 41. The protein complex of any of claims 1-40, wherein the protein complex is a heterodimer.
42. A pharmaceutical preparation comprising a protein complex of any of claims 1-41.

43. The pharmaceutical preparation of claim 42, wherein the protein complex of any of claims 1-40 is at least 80%, 85%, 90%, 95%, 97%, 98% or 99% pure with respect to other polypeptide components.
- 5 44. The pharmaceutical preparation of claim 42 or 43, wherein the pharmaceutical preparation comprises less than 20%, 15%, 10%, 5%, 3%, 2% or 1% of homodimers formed by the self-association of the first or second polypeptides.
- 10 45. A fusion polypeptide comprising an amino acid sequence of a follistatin-related polypeptide and the amino acid sequence of a member of an asymmetric interaction pair.
- 15 46. The fusion polypeptide of claim 45, wherein the amino acid sequence of the follistatin-related polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of any of SEQ ID Nos: 1-33.
- 20 47. The fusion polypeptide of claim 45 or 46, wherein the fusion polypeptide comprises a linker polypeptide positioned between the amino acid sequence of the follistatin-related polypeptide and the amino acid sequence of the member of the asymmetric interaction pair.
- 25 48. The fusion polypeptide of claim 45, 46 or 47, wherein the member of the asymmetric interaction pair comprises a constant domain of an immunoglobulin.
- 30 49. The fusion polypeptide of claim 45, 46 or 47, wherein the member of the asymmetric interaction pair comprises an Fc domain of an immunoglobulin.
50. The fusion polypeptide of claim 45, 46 or 47, wherein the member of the asymmetric interaction pair comprises an amino acid sequence that is an Fc domain of an IgG1, IgG2, IgG3 or IgG4.
51. The fusion polypeptide of claim 45, 46 or 47, wherein the member of the asymmetric interaction pair comprises an amino acid sequence that is at least

80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs: 34-46.

52. The fusion polypeptide of claim 45, 46 or 47, wherein the member of the asymmetric interaction pair comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs: 39-46.
53. The protein complex of claim 1, wherein:
- a. the first polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% to the amino acid sequence of SEQ ID NO: 57; and
 - b. the second polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% to the amino acid sequence of SEQ ID NO: 58.
54. The protein complex of claim 1, wherein:
- a. the first polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% to the amino acid sequence of SEQ ID NO: 71; and
 - b. the second polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% to the amino acid sequence of SEQ ID NO: 72.
55. A nucleic acid comprising a coding sequence for the fusion protein of any one of claims 45-52.

IgG1 -----THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKE 53
 IgG4 ---ESKYGPPCPSCPAPPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQF 57
 IgG2 -----VECPPCPAPPVAG--PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF 51
 IgG3 EPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQF 60
 ** **** . * *****:*****:*

IgG1 NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT 113
 IgG4 NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT 117
 IgG2 NWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQQDWLNGKEYKCKVSNKGLPAPIEKT 111
 IgG3 KQYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT 120
 :*****:***:*****:*****.***:****

IgG1 ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTP 173
 IgG4 ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTP 177
 IgG2 ISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTP 171
 IgG3 ISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTTP 180
 :**:*****.*****:***

IgG1 PVLDS^uSDGSFFLY^uSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 225
 IgG4 PVLDS^uSDGSFFLY^uSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK 229
 IgG2 PMLD^uSDGSFFLY^uSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 223
 IgG3 PMLD^uSDGSFFLY^uSKLTVDKSRWQQGNIFSCSVMHEALHNRF^uTQKSLSLSPGK 232
 *:*****:*****:***:*****:***** **

FIGURE 1

Schematic Heteromeric Protein Complex




FIGURE 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2016/024368

A. CLASSIFICATION OF SUBJECT MATTER

C12N 15/62 (2006.01) C07K 14/495 (2006.01) A61K 38/18 (2006.01) A61K 39/395 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, WPIAP, MEDLINE, BIOSIS, BIOTECHABS, EMBASE, CAPLUS, PATENTSCOPE, AUSPAT, GOOGLE, ESPACENET, PUBMED, GENOMEQUEST (follistatin, WFIKKN, fusion, complex, Fc domain, immunoglobulin, ACCELERON PHARMA INC, KUMAR R, GRINBERG A, SAKO D, SEQ ID NOS: 39-46, 57, 58, 71 and 72)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Documents are listed in the continuation of Box C		



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
7 June 2016Date of mailing of the international search report
07 June 2016

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
Email address: pct@ipaaustralia.gov.au

Authorised officer

Anita Premkumar
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. 0262832013

INTERNATIONAL SEARCH REPORT C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		International application No. PCT/US2016/024368
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 2014/116981 A1 (SHIRE HUMAN GENETIC THERAPIES, INC) 31 July 2014 [0004], [0015], [0016], [0025], [0030], [0032], [0067], [0070], [0115], [0127]-[0133], [0137], [0150]-[0154], [0167], Examples 2, 9 and 10, Table 14, Fig 2, Claim 40-50 SEQ ID NOs: 1 and 2	1-11, 31-34, 37-44, 53 AND 54 46
X	WO 2014/187807 A1 (ARCARIOS B.V.) 27 November 2014 Page 4 lines 16-20, page 7 lines 1-9, Fig 2, Example 2	1, 3-10, 31-34, 37, 38, 42- 44, 53 AND 54
X Y	WO 2007/067616 A2 (AMGEN INC) 14 June 2007 Page 8 last para, page 9 lines 1-3, page 14, page 18 line 11-page 20 line 13, page 20 lines 30-35, page 21 line 23-page 22 line 10, page 43 lines 1-6, page 53 line 14-page 59 line 29, Example 2, Claims 4, 9, 14, 19, 24, 29, 34 and 39. Page 18 line 11-page 20 line 13	1-45 AND 47-55 46
X	US 2003/0162714 A1 (HILL et al) 28 August 2003 [0016]-[0018], [0037], [0053], [0058]-[0062], [0077], [0080], [0089].	1, 3-6, 8, 10, 11, 31-34, 38, 42, 44, 53 AND 54
X	DATTA-MANNAN et al; "An Engineered Human Follistatin Variant: Insights into the Pharmacokinetic and Pharmacodynamic Relationships of a Novel Molecule with Broad Therapeutic Potential." J Pharmacol Exp Ther (March 2013), Vol: 344, Pages 616-623 Abstract, Introduction and Discussion	1, 3-6, 8, 10, 31-34, 38, 42, 44, 53 AND 54
X	YADEN et al "Follistatin: A Novel Therapeutic for the Improvement of Muscle Regeneration." J Pharmacol Exp Ther (May 2014), Vol: 349, Pages 355-371 Abstract, page 356, Discussion	1, 3-6, 8, 10, 31-34, 38, 42, 44, 53 AND 54
P,X	WO 2015/187977 A1 (ACCELERON PHARMA, INC.) 10 December 2015 [0006], [0034], [0057]-[0063], [0099]	1, 3-6, 7, 10, 31-36, 38 AND 42

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/024368

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2014/116981 A1	31 July 2014	WO 2014116981 A1	31 Jul 2014
		AU 2014209178 A1	21 May 2015
		CA 2898121 A1	31 Jul 2014
		CN 104902915 A	09 Sep 2015
		EA 201590719 A1	30 Dec 2015
		EP 2948161 A1	02 Dec 2015
		JP 2016511751 A	21 Apr 2016
		KR 20150111347 A	05 Oct 2015
		MX 2015009631 A	30 Nov 2015
		US 2016083440 A1	24 Mar 2016
WO 2014/187807 A1	27 November 2014	WO 2014187807 A1	27 Nov 2014
WO 2007/067616 A2	14 June 2007	WO 2007067616 A2	14 Jun 2007
		AU 2006321906 A1	14 Jun 2007
		AU 2006321906 B2	09 Sep 2010
		AU 2010214673 A1	16 Sep 2010
		AU 2010214673 B2	12 Sep 2013
		AU 2010214691 A1	16 Sep 2010
		AU 2010214691 B2	12 Sep 2013
		AU 2013213714 A1	22 Aug 2013
		CA 2632544 A1	14 Jun 2007
		CA 2856436 A1	14 Jun 2007
		EP 1968621 A2	17 Sep 2008
		JP 2009518422 A	07 May 2009
		JP 2013028620 A	07 Feb 2013
		JP 2014224115 A	04 Dec 2014
		JP 2016094427 A	26 May 2016
		MX 2008007324 A	04 Mar 2009
		US 2007149458 A1	28 Jun 2007
US 2011008375 A1	13 Jan 2011		
US 2014294866 A1	02 Oct 2014		
US 2003/0162714 A1	28 August 2003	US 2003162714 A1	28 Aug 2003
		US 7192717 B2	20 Mar 2007
		AU 2003217612 A1	09 Sep 2003
		BR 0307907 A2	05 Jul 2011

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/024368

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		CA 2476887 A1	04 Sep 2003
		CN 1929734 A	14 Mar 2007
		EP 1572909 A2	14 Sep 2005
		JP 2005534616 A	17 Nov 2005
		JP 4429729 B2	10 Mar 2010
		JP 2010031018 A	12 Feb 2010
		KR 20040094709 A	10 Nov 2004
		MX PA04008150 A	17 Jun 2005
		NO 20043886 A	16 Sep 2004
		PL 375045 A1	14 Nov 2005
		US 2007134258 A1	14 Jun 2007
		US 7541154 B2	02 Jun 2009
		US 2005106154 A1	19 May 2005
		US 7585835 B2	08 Sep 2009
		US 2010021462 A1	28 Jan 2010
		US 7956038 B2	07 Jun 2011
		WO 03072715 A2	04 Sep 2003
		ZA 200406542 A	28 Feb 2007
WO 2015/187977 A1	10 December 2015	WO 2015187977 A1	10 Dec 2015

End of Annex

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)